Anti-CD47 antibodies and their uses

By designing CD47 antibodies with specific amino acid sequences or their antigen-binding fragments, the problem of erythrocyte agglutination caused by existing antibodies has been solved, achieving more efficient tumor suppression and macrophage phagocytosis, thus meeting clinical needs.

CN115698066BActive Publication Date: 2026-11-10HUTCHMED LIMITED
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
CN202180024295.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-04-10
Filing Date
2021-04-11
Publication Date
2026-11-10
Estimated Expiration
2041-04-11

AI Technical Summary

Technical Problem

Existing CD47 antibodies may cause significant erythrocyte agglutination when treating tumors and have limited effectiveness in inhibiting tumor growth, failing to meet greater clinical needs.

Method used

A novel CD47 antibody or its antigen-binding fragment is provided, comprising specific amino acid sequences of heavy and light chain variable regions, which can efficiently block the interaction between CD47 and SIRPα, inhibit CD47 expression and signal transduction, while avoiding significant erythrocyte agglutination.

Benefits of technology

This antibody significantly inhibited tumor growth and enhanced macrophage phagocytosis in tumor models without causing significant erythrocyte aggregation, demonstrating higher antitumor activity and better potential for clinical application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

This invention provides anti-CD47 antibodies or their antigen-binding fragments, their preparation methods, and their uses for treating or preventing CD47-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to antibodies, and more particularly to anti-CD47 antibodies and their use in the preparation of medicaments for the treatment or prevention of CD47-related diseases. Background Technology

[0002] CD47 (differentiation group 47) was first identified as a tumor antigen for human ovarian cancer in the 1980s. Also known as integrin-associated protein (IAP), ovarian cancer antigen OA3, Rh-associated antigen, and MER6, CD47 is a multi-membrane receptor belonging to the immunoglobulin superfamily. It possesses one immunoglobulin-like domain and five transmembrane domains. As a ligand for signal regulatory protein α (SIRPα), it binds to the V-like domain at the NH2 terminus of SIRPα. SIRPα is primarily expressed in bone marrow cells, including macrophages, granulocytes, dendritic cells (DCs), mast cells, and their precursor cells, including hematopoietic stem cells. On normal cells, CD47 binds to SIRPα on macrophages, releasing a "don't eat me" signal, inhibiting macrophage phagocytosis. This is a crucial mechanism in the innate immune system for macrophages to distinguish between self and non-self. CD47 is widely expressed in human tumor cells and tissues, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, and other solid tumors. Tumor cells evade macrophage phagocytosis and promote tumor growth by binding to SIRPα on the surface of macrophages through highly expressed CD47. The CD47 immune checkpoint is considered a potentially effective and widely applicable target for tumor immunotherapy. Currently, several specific inhibitors targeting the interaction between CD47 and SIRPα have been developed. Multiple preclinical and clinical trials are underway involving drugs for the treatment of diffuse large B-cell lymphoma, acute myeloid leukemia, and advanced solid tumors, including anti-CD47 antibodies and SIRPα fusion proteins. These drugs are administered as monotherapy or in combination with other anti-tumor therapies. For example, in a phase I clinical trial evaluating the efficacy of Hu5F9, an anti-CD47 antibody developed by Forty Seven, in combination with rituximab, 50% of patients who did not respond to rituximab monotherapy achieved an objective response. In clinical data published in 2019, Hu5F9 combined with azacitidine achieved a complete response rate of 36% in 14 patients with relapsed / refractory acute myeloid leukemia, and an even higher response rate of 55% in 11 patients with myelosuppression syndrome.

[0003] This invention provides a novel CD47 antibody or its antigen-binding fragment that exhibits highly efficient antitumor activity without causing significant erythrocyte agglutination, thereby meeting a wider range of clinical needs. Summary of the Invention

[0004] This invention provides anti-CD47 antibodies or antigen-binding fragments thereof that bind to CD47 or fragments thereof, and methods for their preparation and use, including methods for treating CD47-related diseases.

[0005] On one hand, the present invention provides an anti-CD47 antibody or an antigen-binding fragment thereof, comprising one to three HCDR1, HCDR2 and HCDR3 selected from the heavy chain variable region (VH), wherein the amino acid sequence of said VH is as shown in SEQ ID NO: 1, 3, 5, 6 or 7.

[0006] On the one hand, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention contains one or three selected from heavy chain complementarity-determining region 1 (HCDR1), HCDR2 and HCDR3, wherein HCDR1 contains the amino acid sequence shown in SEQ ID NO:11, HCDR2 contains the amino acid sequence shown in SEQ ID NO:12, and HCDR3 contains the amino acid sequence shown in SEQ ID NO:13, 17 or 21.

[0007] On one hand, the present invention provides an anti-CD47 antibody or an antigen-binding fragment thereof, comprising one to three LCDR1, LCDR2 and LCDR3 selected from the light chain variable region (VL), wherein the amino acid sequence of the VL is as shown in SEQ ID NO2, 4, 8, 9 or 10.

[0008] On one hand, the present invention provides an anti-CD47 antibody or an antigen-binding fragment thereof, comprising one to three selected from light chain complementarity-determining regions 1 (LCDR1), LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:15, 18 or 22, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:16.

[0009] In some embodiments, the present invention provides an anti-CD47 antibody or an antigen-binding fragment thereof comprising three CDRs of a heavy chain variable region (VH), namely HCDR1, HCDR2 and HCDR3, and three CDRs of a light chain variable region (VL), namely LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of the VH is as shown in SEQ ID NO: 1, 3, 5, 6 or 7, and the amino acid sequence of the VL is as shown in SEQ ID NO: 2, 4, 8, 9 or 10.

[0010] In some embodiments, the present invention provides an anti-CD47 antibody or an antigen-binding fragment thereof comprising three CDRs of the heavy chain variable region (VH), namely HCDR1, HCDR2, and HCDR3, and three CDRs of the light chain variable region (VL), namely LCDR1, LCDR2, and LCDR3; wherein the VH and VL are selected from:

[0011] (1) VH contains the amino acid sequence shown in SEQ ID NO:1, and VL contains the amino acid sequence shown in SEQ ID NO:2;

[0012] (2) VH contains the amino acid sequence shown in SEQ ID NO:3, and VL contains the amino acid sequence shown in SEQ ID NO:4;

[0013] (3) VH contains the amino acid sequence shown in SEQ ID NO:5, and VL contains the amino acid sequence shown in SEQ ID NO:8, 9 or 10;

[0014] (4) VH contains the amino acid sequence shown in SEQ ID NO:6, and VL contains the amino acid sequence shown in SEQ ID NO:9 or 10; or

[0015] (5) VH contains the amino acid sequence shown in SEQ ID NO:7, and VL contains the amino acid sequence shown in SEQ ID NO:8, 9 or 10.

[0016] In some embodiments, the present invention provides an anti-CD47 antibody or an antigen-binding fragment thereof comprising heavy chain complementarity-determining regions 1 (HCDR1), HCDR2, and HCDR3 and light chain complementarity-determining regions 1 (LCDR1), LCDR2, and LCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:11, HCDR2 comprises the amino acid sequence shown in SEQ ID NO:12, HCDR3 comprises the amino acid sequence shown in SEQ ID NO:13, 17, or 21, LCDR1 comprises the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:15, 18, or 22, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:16.

[0017] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises heavy chain complementarity-determining regions 1 (HCDR1), HCDR2 and HCDR3 and light chain complementarity-determining regions 1 (LCDR1), LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:11, HCDR2 comprises the amino acid sequence shown in SEQ ID NO:12, HCDR3 comprises the amino acid sequence shown in SEQ ID NO:17, LCDR1 comprises the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:18 and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:16.

[0018] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence that is identical to or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1, 3, 5, 6, or 7.

[0019] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a light chain variable region (VL), wherein the VL comprises an amino acid sequence that is identical to or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:2, 4, 8, 9, or 10.

[0020] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence identical to or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1, 3, 5, 6, or 7, and wherein the VL comprises an amino acid sequence identical to or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 2, 4, 8, 9, or 10.

[0021] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence that is identical to or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:7, and wherein the VL comprises an amino acid sequence that is identical to or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:8.

[0022] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL are selected from:

[0023] (1) VH contains the amino acid sequence shown in SEQ ID NO:1 and VL contains the amino acid sequence shown in SEQ ID NO:2;

[0024] (2) VH contains the amino acid sequence shown in SEQ ID NO:3 and VL contains the amino acid sequence shown in SEQ ID NO:4;

[0025] (3) VH contains the amino acid sequence shown in SEQ ID NO:5 and VL contains the amino acid sequence shown in SEQ ID NO:8, 9 or 10;

[0026] (4) VH contains the amino acid sequence shown in SEQ ID NO:6 and VL contains the amino acid sequence shown in SEQ ID NO:9 or 10; or

[0027] (5) VH contains the amino acid sequence shown in SEQ ID NO:7 and VL contains the amino acid sequence shown in SEQ ID NO:8, 9 or 10.

[0028] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:1 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:2.

[0029] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:3 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:4.

[0030] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:5 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:8.

[0031] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:5 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:9.

[0032] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:5 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:10.

[0033] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:6 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:9.

[0034] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:6 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:10.

[0035] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:7 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:8.

[0036] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO:7 and wherein the VL comprises the amino acid sequence of SEQ ID NO:9.

[0037] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:7 and wherein the VL comprises the amino acid sequence shown in SEQ ID NO:10.

[0038] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a heavy chain constant region, such as a human IgG1 constant region, a human IgG4 constant region, a human IgG4P constant region, or a human IgG1TM constant region. The human IgG4P constant region of the present invention is a mutated human IgG4 having an amino acid substitution of S228P (according to EU designation). In some embodiments, the human IgG1TM constant region is a mutated human IgG1 constant region having amino acid substitutions of L234F, L235E, and P331S (according to EU designation).

[0039] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises a light chain constant region, such as a human κ or λ constant region.

[0040] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention is a monoclonal antibody. In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention is a murine antibody, a chimeric antibody, or a humanized antibody. In some embodiments, at least a portion of the frame sequence of the anti-CD47 antibody or its antigen-binding fragment provided by the present invention is a human common frame sequence. In one embodiment, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention is a full-length antibody, a single-domain antibody such as VHH, Fab, Fab', Fab'-SH, (Fab')2, a single-chain antibody such as scFv, Fv, dAb (domain antibody), or a bispecific (multispecific) antibody.

[0041] On the other hand, the present invention provides an isolated nucleic acid that encodes any of the anti-CD47 antibodies or antigen-binding fragments provided by the present invention. Preferably, the nucleic acid encodes the heavy chain or light chain of the antibody of the present invention, or the variable region of the heavy chain or the variable region of the light chain.

[0042] On the other hand, the present invention provides a recombinant vector or expression vector comprising one or more nucleic acids provided by the present invention, wherein the vector is adapted for recombination to generate any of the antibodies or antigen-binding fragments provided by the present invention. In some embodiments, the vector is an expression vector.

[0043] On the other hand, the present invention provides a host cell comprising one or more nucleic acids, recombinant vectors, or expression vectors provided by the present invention.

[0044] On the other hand, the present invention provides an immune conjugate or immune fusion compound comprising the anti-CD47 antibody or its antigen-binding fragment provided by the present invention.

[0045] On the other hand, the present invention provides a pharmaceutical composition comprising an anti-CD47 antibody or an antigen-binding fragment thereof provided by the present invention, a nucleic acid, a carrier or host cell provided by the present invention, and optionally a composition comprising at least one pharmaceutically acceptable pharmaceutical excipient (e.g., a carrier or excipient).

[0046] On the other hand, the present invention provides a method for treating or preventing CD47-related diseases, the method comprising administering to a subject an effective amount of any of the antibodies described herein or their antigen-binding fragments, nucleic acids, vectors or host cells provided by the present invention, immune conjugates or immune fusions provided by the present invention, or pharmaceutical compositions provided by the present invention.

[0047] On the other hand, the present invention also provides the use of the anti-CD47 antibody of the present invention or its antigen-binding fragment in the preparation of a medicament for treating or preventing CD47-related diseases.

[0048] In some implementations, the CD47-related diseases include various hematologic cancers and solid tumors, including but not limited to bladder cancer, colorectal cancer, pancreatic cancer, lymphoma, leukemia, multiple myeloma, (malignant) melanoma, leiomyosarcoma, glioma, glioblastoma, myeloma, endometrial cancer, kidney cancer, (benign) birthmark tumor, prostate cancer, thyroid cancer, cervical cancer, stomach cancer, and liver cancer.

[0049] The anti-CD47 antibody or its antigen-binding fragment of the present invention can also be combined with other therapeutic agents or treatment methods for the treatment or prevention of CD47-related diseases.

[0050] In some embodiments, the antibody or its antigen-binding fragment described in this invention can be used to detect CD47 protein in a sample, or to diagnose / detect CD47-related diseases.

[0051] This invention also covers any combination of any embodiments described herein. Any embodiment described herein, or any combination thereof, is applicable to any and all anti-CD47 antibodies, fragments thereof, methods, and uses of the invention described herein. Attached Figure Description

[0052] Figure 1 The binding activity of antibody HMA02h14-48 to CD47 on the surface of Raji cells was demonstrated.

[0053] Figure 2The binding activity of antibody HMA02h14-48 to CD47 on the surface of Toledo cells was demonstrated.

[0054] Figure 3 The binding activity of antibody HMA02h14-48 to CD47 on the surface of REC-1 cells was demonstrated.

[0055] Figure 4 The activity of antibody HMA02h14-48 in blocking the interaction between human CD47 and SIRPα was demonstrated.

[0056] Figure 5 The effect of antibody HMA02h14-48 on human MΦ phagocytic Raji cells was demonstrated.

[0057] Figure 6 The effect of antibody HMA02h14-48 on human MΦ phagocytic Toledo cells was demonstrated.

[0058] Figure 7 The effect of antibody HMA02h14-48 on human MΦ phagocytic REC-1 cells was demonstrated.

[0059] Figure 8 The effect of antibody HMA02h14-48 on human MΦ phagocytosis of HL-60 cells was demonstrated.

[0060] Figure 9 The effect of antibody HMA02h14-48 on the in vitro agglutination activity of erythrocytes was demonstrated.

[0061] Figure 10 The ability of antibody HMA02h14-48 to bind to CD47 on the surface of human erythrocytes was demonstrated.

[0062] Figure 11 The study demonstrated that Hu5F9 and HMA02h14-48 inhibited the growth of Toledo tumors.

[0063] Figure 12 The study demonstrated that Hu5F9 and HMA02h14-48 inhibited REC-1 tumor growth. Invention Details

[0065] This invention provides an anti-CD47 antibody or its antigen-binding fragment that can block the interaction between CD47 and SIRPα, has highly efficient anti-tumor activity, and does not cause significant levels of erythrocyte agglutination.

[0066] The anti-CD47 antibody or its antigen-binding fragment provided by this invention exhibits inhibitory activity, such as inhibiting CD47 expression (e.g., inhibiting cell surface CD47 expression), activity, and / or signal transduction, or blocking the interaction between CD47 and SIRPα. The CD47 antibody provided by this invention completely or partially reduces or modulates CD47 expression or activity upon binding to or interacting with CD47 (e.g., human CD47). The reduction or modulation of CD47 biological function is complete, significant, or partial following interaction between the antibody and human CD47 polypeptides and / or peptides. The antibody is considered to completely inhibit CD47 expression or activity when the level of CD47 expression or activity is reduced by at least 95% (e.g., 96%, 97%, 98%, 99%, or 100%) in the presence of the anti-CD47 antibody, compared to the level of CD47 expression or activity in the absence of interaction (e.g., binding) with the anti-CD47 antibody described herein. When the expression or activity level of CD47 is reduced by at least 50% (e.g., 55%, 60%, 75%, 80%, 85%, or 90%) in the presence of an anti-CD47 antibody compared to the absence of such binding, the CD47 antibody is considered to significantly inhibit CD47 expression or activity. When the expression or activity level of CD47 is reduced by less than 95% (e.g., 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85%, or 90%) in the presence of an anti-CD47 antibody compared to the absence of such interaction (e.g., binding), the antibody is considered to partially inhibit CD47 expression or activity.

[0067] The anti-CD47 antibody or antigen-binding fragment provided by this invention, compared with the level of interaction between CD47 and SIRPα in the absence of the anti-CD47 antibody or antigen-binding fragment described herein, blocks at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95%, or at least 99% of the interaction between CD47 and SIRPα.

[0068] The anti-CD47 antibody or its antigen-binding fragment of the present invention does not cause significant levels of cell agglutination; for example, the CD47 antibody of the present invention does not cause significant levels of erythrocyte agglutination. In some embodiments, if the erythrocyte agglutination level in the presence of the CD47 antibody of the present invention is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the erythrocyte agglutination level in the presence of the existing CD47 antibody Hu5F9, then the CD47 antibody of the present invention does not cause significant levels of erythrocyte agglutination.

[0069] Compared to antibodies known in the art, the antibodies provided by this invention are also significantly effective in tumor models. In some embodiments, the antibodies provided by this invention are able to significantly inhibit tumor growth. In some embodiments, when the antibodies of this invention are present, tumor volume is inhibited by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99%, or 100%, compared to when said antibodies are absent. For example, compared to the ability of macrophages to phagocytose tumor cells in the presence of existing CD47 antibodies, the ability of macrophages to phagocytose tumor cells in the presence of the CD47 antibodies of this invention is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99%.

[0070] The present invention also provides a method for preparing anti-CD47 antibodies or antigen-binding fragments thereof and their use in applications such as cancer treatment or prevention.

[0071] definition

[0072] Unless otherwise stated, the present invention will be implemented using conventional techniques of molecular biology (including recombinant technology), microbiology, cell biology, biochemistry and immunology, all of which are within the scope of the art.

[0073] To facilitate a better understanding of this invention, certain technical terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, the technical terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains. For specific definitions and terms in this field, those skilled in the art may refer to Current Protocols in Molecular Biology (Ausubel). The abbreviations for amino acid residues are the standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids. The singular forms used herein (including the claims) include their corresponding plural forms unless otherwise expressly specified herein.

[0074] The term “about” refers to a value or composition within an acceptable range of error as determined by one of ordinary skill in the art, depending in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within one or more standard deviations according to practice in the art. Alternatively, “about” can mean a range of up to 5%, 10%, or 20% (i.e., ±5%, ±10%, or ±20%).

[0075] When the term “and / or” is used to connect two or more options, it should be understood to mean any one of the options or any two or more of the options.

[0076] As used herein, the terms “comprising” or “including” mean to include the stated elements, integers, or steps, but do not exclude any other elements, integers, or steps. In this document, when the terms “comprising” or “including” are used, unless otherwise specified, they also cover situations consisting of the mentioned elements, integers, or steps. For example, when referring to an antibody variable region “comprising” a specific sequence, it is also intended to cover the antibody variable region consisting of that specific sequence.

[0077] The terms “integrin-associated protein (IAP)” and “CD47”, when used herein, refer to any native CD47 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats) unless otherwise stated. The term covers “full-length” unprocessed CD47 as well as any form of CD47 or any fragment thereof produced by intracellular processing. The term also includes variants of naturally occurring CD47, such as splice variants or allelic variants. In some embodiments, CD47 refers to the full-length CD47 or a fragment thereof derived from humans (such as the mature fragment lacking its signal peptide). In some embodiments, human CD47 refers to CD47 or a fragment thereof that corresponds to the amino acid sequence shown in NCBI accession number NP_001768.1. In some embodiments, the term also covers fusion proteins containing CD47 or fragments thereof.

[0078] “SIRPα” refers to wild-type signal regulatory protein α, or a recombinant or non-recombinant polypeptide containing the amino acid sequence of wild-type signal regulatory protein α, or a natural or naturally occurring allele variant of signal regulatory protein α.

[0079] The terms "anti-CD47 antibody," "anti-CD47," "CD47 antibody," or "CD47-binding antibody" refer to an antibody or its antigen-binding fragment that binds to the CD47 protein or a fragment thereof with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD47. In some embodiments, the dissociation constant (KD) of the anti-CD47 antibodies provided herein is ≤100 nM, ≤10 nM, ≤5 nM, ≤4 nM, ≤3 nM, ≤2 nM, ≤1 nM, ≤0.9 nM, or ≤0.8 nM. In some embodiments, the antibody or its antigen-binding fragment binds to full-length human CD47 or a fragment thereof (especially its extracellular binding fragment). In some embodiments, the antibody or its antigen-binding fragment binds to a protein containing full-length CD47 or a fragment thereof. In other embodiments, the antibody or its antigen-binding fragment binds to CD47 or a fragment thereof expressed on the cell surface.

[0080] The term "affinity" in this document refers to the strength of the sum of all non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity reflecting a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y can generally be expressed using the dissociation constant (K0). D The term is used to describe this. Examples of analyses known in the art for determining binding affinity include surface plasmon resonance (e.g., BIACORE) or similar techniques (e.g., ForteBio).

[0081] The term "CD47-related disease" in this document refers to non-physiological states related to the expression, function, or activity of CD47 or to CD47-mediated signal transduction activity, including but not limited to cancer. In some embodiments, said disease will benefit from blocking CD47-related signal transduction.

[0082] The terms “immune response” or “immune reaction” used in this article are used interchangeably and refer to the action of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules (including antibodies, cytokines, and complement) produced by the aforementioned cells or the liver, which results in selective damage, destruction, or clearance from the body of invading pathogens, pathogen-infected cells or tissues, cancer cells, or normal human cells or tissues in cases of autoimmunity or pathological inflammation.

[0083] The term "signal transduction" in this article refers to a biochemical causal relationship, typically initiated by protein-protein interactions such as the binding of CD47 to its receptor, that results in the transmission of a signal from one part of the cell to another. Generally, transduction involves the specific phosphorylation of one or more tyrosine, serine, or threonine residues on one or more proteins in a series of reactions that induce signal transduction. The penultimate process typically involves nuclear events that lead to changes in gene expression.

[0084] The terms “activity” or “bioactivity”, or “biological property” or “biocharacteristic”, used herein are interchangeable and include, but are not limited to, epitope / antigen affinity and specificity, the ability to neutralize or antagonize CD47 activity in vivo or in vitro, the ability to enhance or activate CD47 activity, and IC50. 50 The in vivo stability and immunogenic properties of antibodies. Other identifiable biological properties or characteristics of antibodies known in the art include, for example, cross-reactivity (i.e., cross-reactivity with non-human homologs of the target peptide, or with other proteins or tissues), and the ability to maintain high expression levels of antibodies in mammalian cells. The aforementioned properties or characteristics can be observed, measured, or evaluated using techniques known in the art, including, but not limited to, ELISA, FACS, or BIACORE plasma resonance analysis, in vitro or in vivo neutralization assays, receptor binding, production and / or secretion of cytokines or growth factors, signal transduction, and immunohistochemistry of tissue sections from various sources (including human, primate, or any other source).

[0085] The term "antibody" in this document refers to any form of antibody that has the desired biological activity. Therefore, it is used in the broadest sense and specifically includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, human antibodies, chimeric antibodies, CrossMab antibodies, or camel-derived single-domain antibodies.

[0086] The terms "whole antibody," "full-length antibody," and "intact antibody" are used interchangeably herein to refer to a glycoprotein comprising at least two heavy chains (H) and two light chains (L) linked together by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains: CH1, CH2, and CH3. Each light chain consists of a light chain variable region (abbreviated as VL) and a light chain constant region. The light chain constant region consists of one domain: CL. The VH and VL regions can be further subdivided into hypervariable regions (complementarity-determining regions (CDRs), interspersed with more conserved regions (framework regions (FRs)). A "complementarity-determining region" or "CDR" is a region within the antibody's variable domain that is highly variable in sequence and forms a structurally defined loop ("hypervariable loop") and / or contains antigen contact residues ("antigen contact sites"). CDRs are primarily responsible for binding to antigen epitopes. Heavy and light chain CDRs are typically referred to as CDR1, CDR2, and CDR3, starting from the N-terminus. Sequential numbering. CDRs located within the variable domain of the antibody heavy chain are sequentially named HCDR1, HCDR2, and HCDR3, while CDRs located within the variable domain of the antibody light chain are sequentially named LCDR1, LCDR2, and LCDR3. Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Constant regions do not directly participate in antibody-antigen binding but exhibit various effector functions.

[0087] In a given VH or VL amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any of a number of known schemes or combinations thereof, including, for example: the Chothia scheme (Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, Journal of Molecular Biology, 196, 901-917 (1987)); the Kabat scheme (Kabat et al., Sequences of Proteins of Immunological Interest, 4th edition, USDapartment of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), and Contact (University College London); and the North scheme (North et al., A New Clustering of Antibody CDR Loop Conformations, Journal of Molecular Biology, 406, 228-256 (2011)). The boundaries of the CDRs of the anti-CD47 antibody in this invention can be determined according to any scheme or combination thereof in the art and through human evaluation.

[0088] Antibody light chains can be classified into one of two types (called kappa (κ) and lambda (λ)) based on the amino acid sequence of their constant structural domains. Antibody heavy chains can be classified into five main types based on the amino acid sequence of their heavy chain constant regions: IgA, IgD, IgE, IgG, and IgM, and several of these types can be further subdivided into subclasses, such as IgG1, IgG2, IgG3 and IgG4, IgA1, and IgA2.

[0089] "Antibody in IgG form" refers to an antibody whose heavy chain constant region is derived from IgG4. For example, antibody in IgG4 form means that its heavy chain constant region is derived from IgG4.

[0090] The term "monoclonal antibody" in this document refers to an antibody derived from a basic homogeneous group of antibodies, meaning that the individual antibodies comprising this group are identical except for the possibility of naturally occurring mutations, which may be present in small amounts. Monoclonal antibodies are highly specific, targeting a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically comprise a large number of antibodies targeting different epitopes (or specific to different epitopes). The modifier "monoclonal" indicates the characteristic of antibodies derived from a basic homogeneous group of antibodies and should not be construed as requiring the production of antibodies through any particular method.

[0091] The term "antigen-binding fragment" as used herein refers to a fragment or derivative of an antibody, typically comprising at least one fragment (e.g., one or more CDRs) of the antigen-binding region or variable region of the antibody and retaining at least some of the binding properties of the antibody. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; biantibodies; linear antibodies; single-chain antibody molecules, such as sc-Fv; nanobodies formed from antibody fragments; and multispecific antibodies. When antigen-binding activity is expressed on a molar concentration basis, the binding fragment or derivative typically retains at least 10% of the antigen-binding activity of its source antibody. Preferably, the binding fragment or derivative retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or higher of the antigen-binding activity of its source antibody.

[0092] It is anticipated that antibodies or their antigen-binding fragments may include conserved or non-conserved amino acid substitutions that do not significantly alter their biological activity (referred to as “conserved variants” or “functionally conserved variants” of antibodies). In a preferred aspect, the conserved substitutions are derived from the conserved substituted residues shown in Table A below, preferably the preferred conserved amino acid substituted residues shown in Table A.

[0093] Table A

[0094]

[0095]

[0096] An epitope is an antigenic region to which an antibody binds. Epitopes can be formed from consecutive amino acids or from discontinuous amino acids juxtaposed through the ternary folding of a protein.

[0097] The term “isolated anti-CD47 antibody or antigen-binding fragment thereof” in this document refers to the purified state of the anti-CD47 antibody or antigen-binding fragment thereof. For example, “isolated” may mean that the molecule is substantially free of other biomolecules, such as nucleic acids, proteins, lipids, sugars, or other substances such as cell debris and growth media. However, as those skilled in the art will appreciate, the term “isolated” does not mean the complete absence of such substances or the absence of water, buffers, or salts, unless they are present in amounts that would significantly interfere with the experimental or therapeutic application of the antibody described herein. In some embodiments, the isolated antibody or antigen-binding fragment may have a purity greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%, which is determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for evaluating antibody purity, see, for example, Flatman, S. et al., J. Chrom. B 848 (2007) 79-87.

[0098] The term "chimeric antibody" in this article refers to an antibody possessing a variable domain of a first antibody and a constant domain of a second antibody, wherein the first and second antibodies originate from different species. Typically, the variable domain is derived from antibodies from laboratory animals such as rodents, while the constant domain sequence is derived from human antibodies. This results in chimeric antibodies being less likely to induce adverse immune responses in human subjects compared to antibodies from the aforementioned laboratory animals.

[0099] The term "humanized antibody" as used herein refers to an antibody form containing sequences derived from human and non-human (e.g., mouse, rat) antibodies. Generally, a humanized antibody comprises at least one, typically two, variable domains, wherein all or substantially all of the hypervariable loops correspond to the hypervariable loops of a non-human immunoglobulin, and all or substantially all of the framework (FR) regions are framework regions of a human immunoglobulin. Optionally, a humanized antibody may contain at least a portion of the constant region (Fc) of a human immunoglobulin. In some cases, as is known to those skilled in the art, amino acid mutations may be introduced into the humanized antibody (e.g., variable domains, framework regions, and / or constant regions (if present)) to, for example, improve certain properties of the antibody; such antibody forms still fall within the scope of the "humanized antibody" of this invention.

[0100] As those skilled in the art will appreciate, antibodies can have a glycan form suitable for the cells used to produce the antibody. For example, when produced in mice, in mouse cells, or in hybridomas derived from mouse cells, antibodies may contain mouse glycans. Alternatively, if produced in rats, in rat cells, or in hybridomas derived from rat cells, antibodies may contain rat glycans.

[0101] The term "Fc region" is used in this document to define a C-terminal region in an immunoglobulin heavy chain that contains at least a portion of a constant region. This term includes native sequence Fc regions and Fc region variants. Native sequence Fc regions encompass the various naturally occurring immunoglobulin Fc sequences, such as the Fc regions of various Ig subtypes and their allotypes (Gestur Vidarsson et al., IgG subclasses and allotypes: from structure to effector functions, 20 October 2014, doi:10.3389 / fimmu.2014.00520.). In one embodiment, the human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the C-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, amino acid residues in the Fc region or constant region are numbered according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0102] The terms "Fc variant" or "variant Fc region" used herein are interchangeable and refer to an Fc region containing modifications relative to the native sequence Fc region. The Fc variants of this invention are defined according to the amino acid modifications that constitute them.

[0103] The term "pharmaceutical excipients" refers to diluents, adjuvants (e.g., Freund's adjuvants (complete and incomplete)), excipients, carriers, or stabilizers that are applied together with the active substance.

[0104] The term "pharmaceutical composition" refers to a composition which is present in a form that allows the biological activity of the active ingredient contained therein to be effective, and which does not contain any additional ingredients that would have unacceptable toxicity to a subject administering the composition.

[0105] In this article, "immunoconjugate" is an antibody conjugated to one or more other substances (including but not limited to cytotoxic agents or labels). "Immunofusion" is an antibody fused to one or more other peptides or polypeptides via covalent linkage.

[0106] The term "therapeutic agent" as used in this article covers any substance that is effective in preventing or treating related diseases, such as cancer.

[0107] The term "cytotoxic agent" is used in this invention to refer to substances that inhibit or prevent cell function and / or cause cell death or damage.

[0108] "Chemotherapy agents" include small chemical molecule drugs that are useful in treating cancer or immune system diseases.

[0109] The term "small molecule drug" refers to low-molecular-weight organic compounds capable of modulating biological processes. "Small molecule" is defined as a molecule with a molecular weight less than 10 kDa, typically less than 2 kDa, and preferably less than 1 kDa. Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing inorganic components, molecules containing radioactive atoms, synthetic molecules, peptide mimics, and antibody mimics. As therapeutic agents, small molecules can penetrate cells more readily, are less susceptible to degradation, and are less likely to elicit an immune response than large molecules.

[0110] As used herein, the term "immunomodulator" refers to a natural or synthetic active agent or drug that modulates (suppresses or enhances) an immune response. An immune response can be a humoral or cellular response. Immunomodulators include immunosuppressants. In some embodiments, immunomodulators contain active agents or drugs that enhance immune responses, for example, active agents or drugs that are beneficial in enhancing anti-cancer immune responses during cancer treatment.

[0111] As used in this article, “immunosuppressant,” “immunosuppressive drug,” or “immunosuppressant” refers to a therapeutic agent used in immunosuppressive therapy to suppress or prevent the activity of the immune system.

[0112] The terms “cancer” and “cancer malignancy” refer to or describe a physiological disorder in mammals characterized by unregulated cell growth. This definition includes both benign and malignant cancers, as well as dormant tumors or micrometastases. Cancer includes, but is not limited to, solid tumors and hematologic malignancies. Examples of various cancers include, but are not limited to, carcinomas, lymphomas, germ cell tumors, sarcomas, and leukemias.

[0113] The term "vector" in this document refers to any recombinant polynucleotide construct that can be used for transformation purposes (i.e., introducing heterologous DNA into host cells). One type of vector is the "plasmid," which is a circular double-stranded DNA loop into which an additional DNA segment can be ligated. Another type of vector is the viral vector, in which an additional DNA segment can be ligated into a viral genome. Some vectors are capable of autonomous replication in the host cells they are introduced into (e.g., bacterial vectors with bacterial origins of replication and free-living mammalian vectors). After introduction into the host cell, other vectors (e.g., non-free-living mammalian vectors) integrate into the host cell's genome and thus replicate along with the host genome. Furthermore, some vectors can guide the expression of operatively linked genes. This document refers to such vectors as "expression vectors," which are nucleic acids capable of replicating and expressing a target gene upon transformation, transfection, or transduction into host cells. Expression vectors contain one or more phenotypic selection markers and origins of replication to ensure the maintenance of the vector and to provide amplification within the host when needed.

[0114] The terms “subject” or “patient” or “individual” in this article include any human or non-human animal. The term “non-human animal” includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cattle, chickens, amphibians, reptiles, etc.

[0115] The terms "therapeutic effective amount," "therapeutic effective dose," and "effective amount" in this document refer to the amount of the anti-CD47 antibody or its antigen-binding fragment of the present invention, when administered alone or in combination with other therapeutic agents to cells, tissues, or subjects, that effectively prevents or improves the symptoms of one or more diseases or conditions, or the development of such diseases or conditions. Therapeutic effective dose also refers to an amount of antibody or its antigen-binding fragment sufficient to cause symptom improvement, such as an amount that treats, cures, prevents, or improves the associated medical condition, or accelerates the treatment, cure, prevention, or improvement of such conditions. When administered to an individual as a single active ingredient, the therapeutic effective dose refers only to that ingredient. When administered in combination, the therapeutic effective dose refers to the combined amount of active ingredients that cause the therapeutic effect, whether administered in combination, sequentially, or simultaneously. The effective amount of the therapeutic agent will result in an increase of at least 10%, typically at least 20%, preferably at least about 30%, more preferably at least 40%, and most preferably at least 50% in diagnostic criteria or parameters.

[0116] In this document, "treatment" includes 1) therapeutic measures that cure, alleviate, or reduce the symptoms of a diagnosed pathological condition or disease and / or halt the progression of the diagnosed pathological condition or disease, and 2) preventive or preventative measures that prevent and / or alleviate the development of a pathological condition or disease. Therefore, the treater includes an individual who has already contracted the disease, an individual who is susceptible to the disease, and an individual who wishes to prevent the disease. In some embodiments, the present invention relates to the treatment of a disease or symptom; in other embodiments, the present invention relates to the prevention of a disease or symptom.

[0117] In some embodiments of the invention, “treatment” for a disease or symptom means improving the disease or symptom (i.e., slowing or halting or reducing the progression of the disease or at least one of its clinical symptoms). In other embodiments, “treatment” means alleviating or improving at least one bodily parameter, including those physical parameters that may not be identifiable by the patient. In still other embodiments, “treatment” means regulating the disease or symptom physically (e.g., stabilization of identifiable symptoms), physiologically (e.g., stabilization of bodily parameters), or in both ways. Unless explicitly described herein, methods for assessing the treatment and / or prevention of diseases are generally known in the art.

[0118] In further embodiments of the invention, “prevention” of a disease or symptom includes the suppression of the occurrence or development of a disease or symptom, or a symptom of a particular disease or symptom. In some embodiments, subjects with a family history of cancer are candidates for preventative programs. Generally, in the context of cancer, the term “prevention” refers to the administration of a drug prior to the occurrence of signs or symptoms of cancer, particularly prior to their occurrence in subjects at risk of cancer.

[0119] In some embodiments, cancer is considered successfully treated by the method of the present invention if the patient exhibits one or more of the following: a reduction or complete disappearance of the number of cancer cells; a reduction in tumor size; inhibition or absence of cancer cell infiltration into peripheral organs, including, for example, cancer spread to soft tissues and bone; inhibition or absence of tumor metastasis; inhibition or absence of tumor growth; relief of one or more symptoms associated with the specific cancer; reduction in morbidity and mortality; improvement in quality of life; reduction in tumorigenesis, tumorigenesis frequency, or tumorigenesis capacity; reduction in the number or frequency of cancer stem cells in the tumor; differentiation of tumorigenesis cells into a non-tumorigenesis state; or a combination of some of these effects.

[0120] "Inhibition of tumor growth" refers to any mechanism by which tumor cell growth can be suppressed. In some embodiments, tumor cell growth is suppressed by delaying tumor cell proliferation. In some embodiments, tumor cell growth is suppressed by stopping tumor cell proliferation. In some embodiments, tumor cell growth is suppressed by killing tumor cells. In some embodiments, tumor cell growth is suppressed by inducing tumor cell apoptosis. In some embodiments, tumor cell growth is suppressed by inducing tumor cell differentiation. In some embodiments, tumor cell growth is suppressed by depriving tumor cells of nutrients. In some embodiments, tumor cell growth is suppressed by preventing tumor cell migration. In some embodiments, tumor cell growth is suppressed by preventing tumor cell invasion.

[0121] In this document, “sequence identity” refers to the degree of sequence similarity on a nucleotide-by-nucleotide or amino acid-by-amino acid basis within a comparison window. “(Percentage) sequence identity” can be calculated as follows: Two optimally aligned sequences are compared within a comparison window, and the number of positions in the two sequences containing the same nucleic acid bases (e.g., A, T, C, G, I) or the same amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) is determined to obtain the number of matching positions. The number of matching positions is divided by the total number of positions in the comparison window (i.e., the window size), and the result is multiplied by 100 to produce the percentage of sequence identity. Optimal alignments for determining the percentage of sequence identity can be performed in various ways known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNASTAR) software. Those skilled in the art can determine suitable parameters for sequence alignment, including any algorithms required to achieve maximum alignment across the full-length sequence being compared or within the target sequence region. In this invention, for antibody sequences, the percentage of amino acid sequence identity is determined by optimally aligning the candidate antibody sequence with a reference antibody sequence, preferably according to the Kabat numbering rules.

[0122] The term "agglutination" in this article refers to cell clumping, while the term "hemagglutination reaction" refers to the clumping of a specific type of cell (i.e., red blood cells). Therefore, a hemagglutination reaction is a type of agglutination.

[0123] The control antibody “Hu5F9” in this article is an anti-CD47 antibody in IgG4P form recombinantly expressed using GenScript based on the 5F9 variable region sequence disclosed in patent US2015 / 0183874A1. The control antibody “SRF231” is an anti-CD47 antibody in IgG4P form recombinantly expressed using GenScript based on the 2.3D11 variable region sequence disclosed in patent US20180201677A1.

[0124] Anti-CD47 antibodies and their production

[0125] The antibodies of the present invention can be produced using any suitable method for antibody production. Any suitable form of CD47 can be used as an immunogen (antigen) for antibody production. By way of example and not limitation, any CD47 variant or fragment thereof can be used as an immunogen. In some embodiments, hybridoma cells that produce murine monoclonal anti-human CD47 antibodies can be produced by methods known in the art. These methods include, but are not limited to, the hybridoma technique originally developed by Kohler et al. (1975) (Nature 256:495-497). Preferably, according to a standard protocol, mouse spleen cells are isolated and fused with a mouse myeloma cell line using PEG or by electrofusion. Hybridoma cells that secrete antibodies with CD47 binding activity are then screened. The DNA sequence of the immunoglobulin variable region of the hybridoma cells of the present invention can be determined using a degenerate primer-based PCR method.

[0126] Antibodies derived from rodents (such as mice) can induce unwanted antibody immunogenicity when used as therapeutic agents in vivo. Repeated use can lead to an immune response against the therapeutic antibody, which at least results in loss of therapeutic efficacy and, in severe cases, a potentially fatal allergic reaction. One approach to reducing the immunogenicity of rodent antibodies involves the production of chimeric antibodies, in which the variable region of a mouse antibody is fused with a human constant region (Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-43). However, the retention of the intact rodent variable region in chimeric antibodies can still induce harmful immunogenicity in patients.

[0127] Transplanting rodent variable region CDRs onto human frameworks (i.e., humanization) has been used to further minimize rodent sequences. The humanized antibody described in this invention allows insertion of mouse CDR regions into human germline framework regions using methods known in the art. See U.S. Patent No. 5,225,539 to Winter et al. and U.S. Patents 5,530,101, 5,585,089, 5,693,762, and 6,180,370 to Queen et al. However, CDR loop exchange still does not uniformly produce antibodies with the same binding properties as the starting antibody. In humanized antibodies, framework residue (FR) alterations (residues involved in CDR loop support) are often required to maintain antigen-binding affinity. Kabat et al. (1991) J. Immunol. 147:1709. In short, the humanization process involves the following steps: A) Comparing the gene sequences of each candidate antibody with the human embryonic line antibody gene sequence to identify sequences with high homology; B) Analyzing and examining HLA-DR affinity to select human embryonic line framework sequences with low affinity; C) Using computer simulation technology, applying molecular docking analysis to the variable region and its surrounding framework amino acid sequences to examine their spatial stereobinding mode. By calculating electrostatic forces, van der Waals forces, hydrophilicity / hydrophobicity, and entropy values, the key amino acid individuals in each candidate antibody gene sequence that can interact with CD47 and maintain the spatial framework are analyzed. These are then grafted back into the selected human embryonic line gene framework, and based on this, the amino acid sites in the framework region that must be retained are identified, and humanized antibodies are synthesized.

[0128] The precise amino acid sequence boundary of the variable region CDR of the antibody of the present invention can be determined using any of many known schemes (e.g., Kabat, Chothia, AbM, Contact, or North). It should be noted that the boundaries of the CDR of the variable region of the same antibody may differ based on different definition systems. That is, the CDR sequence of the variable region of the same antibody defined under different assignment systems may differ. Therefore, when referring to antibodies defined with a specific CDR sequence as defined in this invention, the scope of said antibody also includes antibodies whose variable region sequence contains the specific CDR sequence, but whose claimed CDR boundary differs from the specific CDR boundary defined in this invention due to the application of different schemes (e.g., different assignment systems or combinations).

[0129] In some embodiments, the CDR boundary of the anti-CD47 antibody molecule provided by the present invention is determined based on the Kabat assignment system.

[0130] Antibodies with different specificities (i.e., different binding sites against different antigens) have different CDRs. However, although CDRs differ between antibodies, only a limited number of amino acid sites within a CDR are directly involved in antigen binding. Using at least two of the Kabat, Chothia, AbM, Contact, and North methods, a minimal overlapping region can be determined, thus providing a “minimum binding unit” for antigen binding. The minimum binding unit can be a sub-part of a CDR. As will be apparent to those skilled in the art, the residues of the remaining portion of the CDR sequence can be determined by the antibody’s structure and protein folding. Therefore, any variants of the CDR given herein are also contemplated in this invention. In some embodiments, in a variant of a CDR of the anti-CD47 antibody of the present invention or its antigen-binding fragment, the amino acid residues of the minimum binding unit may remain unchanged, while the remaining CDR residues as defined by Kabat or IMGT may be replaced by conserved amino acid residues.

[0131] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises one to three selected from heavy chain complementarity-determining region 1 (HCDR1), HCDR2, and HCDR3, wherein HCDR1 comprises an amino acid sequence that is identical to or has at least one and no more than three, two, or one amino acid change (preferably amino acid substitution, preferably conservative substitution) compared to the amino acid sequence of SEQ ID NO:11; HCDR2 comprises an amino acid sequence that is identical to or has at least one and no more than three, two, or one amino acid change (preferably amino acid substitution, preferably conservative substitution) compared to the amino acid sequence of SEQ ID NO:12; and HCDR3 comprises an amino acid sequence that is identical to or has at least one and no more than three, two, or one amino acid change (preferably amino acid substitution, preferably conservative substitution) compared to the amino acid sequence of SEQ ID NO:13, SEQ ID NO:17, or SEQ ID NO:21.

[0132] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention comprises one to three selected from light chain complementarity-determining region 1 (HCDR1), LCDR2, and LCDR3, wherein LCDR1 comprises an amino acid sequence that is identical to or has at least one and no more than three, two, or one amino acid change (preferably an amino acid substitution, preferably a conservative substitution) compared to the amino acid sequence of SEQ ID NO:14; LCDR2 comprises an amino acid sequence that is identical to or has at least one and no more than three, two, or one amino acid change (preferably an amino acid substitution, preferably a conservative substitution) compared to the amino acid sequence of SEQ ID NO:15, SEQ ID NO:18, or SEQ ID NO:22; and LCDR3 comprises an amino acid sequence that is identical to or has at least one and no more than three, two, or one amino acid change (preferably an amino acid substitution, preferably a conservative substitution) compared to the amino acid sequence of SEQ ID NO:16.

[0133] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention further encompasses an antibody or its antigen-binding fragment wherein, on the three CDRs of the heavy chain variable region, relative to the three CDRs specifically disclosed herein, a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid alteration (preferably amino acid substitution, preferably conservative substitution) is included, and / or on the three CDRs of the light chain variable region, relative to the three CDRs specifically disclosed herein, a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid alteration (preferably amino acid substitution, preferably conservative substitution) is included.

[0134] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention further encompasses an antibody or its antigen-binding fragment wherein, compared to the heavy chain variable region and / or light chain variable region of the antibody specifically disclosed herein, the heavy chain variable region and / or light chain variable region has one or more (preferably no more than 10, more preferably no more than 6, 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conserved amino acid substitutions) in its amino acid sequence, preferably, the amino acid changes do not occur in the CDR region.

[0135] In some embodiments, the anti-CD47 antibody or its antigen-binding fragment provided by the present invention has a heavy chain variable region (VH) comprising an amino acid sequence identical to or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with an amino acid sequence selected from SEQ ID NO: 1, 3, 5, 6, or 7. In some embodiments, the anti-CD47 antibody or its antigen-binding fragment of the present invention has a light chain variable region (VL) comprising an amino acid sequence identical to or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with an amino acid sequence selected from SEQ ID NO: 2, 4, 8, 9, or 10.

[0136] In one embodiment of the invention, the amino acid alterations described herein include the substitution, insertion, or deletion of amino acids. Preferably, the amino acid alterations described herein are amino acid substitutions, and more preferably, conservative substitutions.

[0137] In a preferred embodiment, the amino acid change described in this invention occurs in a region outside the CDR (e.g., in the FR). More preferably, the amino acid change described in this invention occurs in a region outside the heavy chain variable region and / or outside the light chain variable region. In some embodiments, the amino acid change occurs in the heavy chain constant region and / or the light chain constant region.

[0138] In some embodiments, the antibodies of the present invention containing amino acid modifications have properties comparable to or similar to the specific antibodies disclosed herein.

[0139] In some embodiments, the anti-CD47 antibody of the present invention includes post-translational modifications to the CDR, light chain variable region, heavy chain variable region, light chain, or heavy chain.

[0140] In some embodiments, the anti-CD47 antibody provided by the present invention is a full-length antibody, a single-domain antibody such as VHH, Fab antibody, Fab' antibody, Fab'-SH, (Fab')2 antibody, a single-chain antibody such as scFv, Fv, dAb (domain antibody), or a bispecific (multispecific) antibody.

[0141] In some embodiments, the anti-CD47 antibody provided by the present invention is an antibody in any IgG form, such as IgG1, IgG2, IgG3, or IgG4. In some embodiments, the anti-CD47 antibody of the present invention is an antibody in the form of IgG4P, i.e., the hinge region within the constant region of human IgG4 is modified with Ser228Pro (S228P, according to EU designation) to avoid or reduce chain exchange.

[0142] In some embodiments, the antibody Fc region provided by the present invention can be modified with one or more amino acids to generate Fc region variants. Fc region variants may comprise human Fc region sequences (e.g., the Fc region of human IgG1, IgG2, IgG3, or IgG4) containing amino acid modifications (e.g., substitutions) at one or more amino acid positions, such as those in Bruhns and... In an article published in Immunol Rev. 2015 Nov; 268(1):25-51, on page 44, several modifications of human IgG1 to enhance or reduce its binding to FcγR and enhance or reduce the corresponding function were summarized.

[0143] In some embodiments, the anti-CD47 antibody provided by the present invention comprises an Fc region variant having reduced or absent FcγR binding activity. In some embodiments, the Fc region variant has amino acid substitutions, specifically, the amino acid substitutions are selected from those at positions E233, L234, L235, N297, and P331 of the immunoglobulin heavy chain, with additional amino acid substitutions. In some embodiments, the amino acid substitutions of the Fc region variant are E233P, L234A, L235A, L235E, N297A, N297D, or P331S.

[0144] In some embodiments, the antibodies provided herein are modified to increase or decrease the degree of antibody glycosylation. The addition or deletion of glycosylation sites on an antibody can be conveniently achieved by altering the amino acid sequence to create or remove one or more glycosylation sites. Glycosylation can be modified to, for example, increase the antibody's affinity for an "antigen." This modification can be accomplished, for example, by altering one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be performed, resulting in the elimination of one or more variable region framework glycosylation sites, thereby eliminating the glycosylation at that site. This glycosylation-free process can increase the antibody's affinity for the antigen. Such methods are described, for example, in U.S. Patent No. 5,426,300. When an antibody contains an Fc region, the sugars attached thereto can be modified. In some applications, modifications to remove unwanted glycosylation sites are useful, such as removing the fucose module to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) function. In other applications, galactosylation modifications can be performed to modify complement-dependent cytotoxicity (CDC).

[0145] In some implementations, it may be necessary to produce cysteine-engineered antibodies, such as "thioMAb", in which one or more residues of the antibody are replaced with cysteine ​​residues.

[0146] In some embodiments, the antibodies provided herein may be further modified to contain other non-protein portions known and readily available in the art. These non-protein portions include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-diane, poly-1,3,6-triane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.

[0147] antibody expression

[0148] The present invention relates to host cells comprising one or more expression vectors and methods for generating any antibody or antigen-binding fragment thereof of the present invention, the methods comprising culturing the host cells, purifying and recovering the antibody or antigen-binding fragment.

[0149] In one aspect, the present invention provides nucleic acids encoding any of the above-described anti-CD47 antibodies or their antigen-binding fragments. For example, the present invention provides nucleic acids encoding heavy chains, light chains, variable regions, or complementarity-determining regions as described herein. In some aspects, the nucleic acid encoding the heavy chain variable region has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the nucleic acid shown in SEQ ID NO:19. In some aspects, the nucleic acid encoding the light chain variable region has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the nucleic acid shown in SEQ ID NO:20.

[0150] In one aspect, one or more vectors containing the nucleic acid are provided. In some embodiments, the vector is an expression vector. The choice of expression vector depends on the intended host cell in which the vector is to be expressed. Typically, the expression vector contains a promoter and other regulatory sequences (e.g., enhancers) operatively linked to a nucleic acid encoding an anti-CD47 antibody chain or an antigen-binding fragment thereof. In some embodiments, the expression vector also contains a sequence encoding the constant region of the antibody. In some embodiments, the expression vector is a PTT5 vector or a pCDNA vector, such as pCDNA3.4.

[0151] In one aspect, the present invention provides host cells, including prokaryotic or eukaryotic cells, for expressing the recombinant antibodies of the present invention. In some embodiments, *Escherichia coli* is a prokaryotic host that can be used to clone and express the polynucleotides of the present invention. Other suitable microbial hosts include bacilli, such as *Bacillus subtilis*, and other Enterobacteriaceae, such as *Salmonella*, *Serratia marcescens*, and various *Pseudomonas* species. Expression vectors can also be prepared in these prokaryotic hosts, which typically contain expression control sequences (e.g., origin of replication) compatible with the host cells. In some embodiments, mammalian host cells are used to express and produce the anti-CD47 antibody peptide of the present invention. For example, they can be hybridoma cell lines expressing endogenous immunoglobulin genes or mammalian cell lines with exogenous expression vectors, including normal human cells or immortalized animal or human cells. For example, many suitable host cell lines capable of secreting intact immunoglobulins have been developed, including CHO cell lines, various COS cell lines, Expire293 cells, HEK293 cells, myeloma cell lines, transformed B cells, and hybridomas.

[0152] In one aspect, the present invention provides a method for preparing anti-CD47 antibodies, wherein the method includes introducing an expression vector into mammalian host cells, culturing the host cells for a sufficient period of time to allow the antibody to be expressed in the host cells, or more preferably, secreting the antibody into a culture medium in which the host cells are grown, to produce the antibody. The antibody can be recovered from the culture medium using standard protein purification methods. The antibody molecules prepared as described herein can be purified using known prior art techniques such as high-performance liquid chromatography, ion-exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, etc. The actual conditions used to purify a particular protein also depend on factors such as net charge, hydrophobicity, and hydrophilicity, and these are obvious to those skilled in the art. The purity of the antibody molecules of the present invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high-performance liquid chromatography, etc.

[0153] Antibodies expressed in different cell lines or in transgenic animals are likely to have different glycosylations. However, all antibodies encoded by the nucleic acids provided herein or containing the amino acid sequences provided herein are part of this invention, regardless of their glycosylation.

[0154] Determination method

[0155] The anti-CD47 antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity using a variety of assays known in the art. On one hand, the antigen-binding activity of the antibodies of the present invention can be tested, for example by known methods such as ELISA, Western blotting, etc. Binding to CD47 can be determined using methods known in the art, and exemplary methods are disclosed herein.

[0156] This invention also provides an assay for identifying biologically active anti-CD47 antibodies. Biological activity may include, for example, binding to CD47 (e.g., binding to human CD47), binding to cell surface CD47, blocking effects on CD47 and its ligands, effects on promoting erythrocyte agglutination activity, and effects on the phagocytic activity of human macrophages against tumor cells. Antibodies exhibiting such biological activity in vivo and / or in vitro are also provided. In some embodiments, the antibodies of this invention are tested for such biological activity.

[0157] Cells used for any of the above in vitro assays include cell lines that naturally express CD47 or are engineered to express CD47, such as tumor cell lines. This class of cells also includes cell lines that express CD47 and cell lines transfected with DNA encoding CD47 that do not normally express CD47.

[0158] It is understood that the immunoconjugates or immunofusions of the present invention can be used to replace or supplement the anti-CD47 antibody for any of the above-described assays.

[0159] Understandably, any of the above assays can be performed using a combination of anti-CD47 antibodies and other active agents.

[0160] Immunoconjugates and Immunofusion Compounds

[0161] In some embodiments, the present invention provides an immunoconjugate comprising any anti-CD47 antibody or its antigen-binding fragment provided herein, and other substances. In one embodiment, the other substances include, for example, cytotoxic agents, comprising any agents harmful to cells.

[0162] In some embodiments, the present invention provides an immunofusion comprising any provided anti-CD47 antibody or its antigen-binding fragment.

[0163] In some embodiments, the immune conjugate and the immune fusion are used to prevent or treat CD47-related diseases.

[0164] Pharmaceutical Composition

[0165] The term "pharmaceutical composition" refers to a formulation in which the active ingredient contained herein is present in a biologically effective form and does not contain any additional ingredients that would have unacceptable toxicity to a subject administering the formulation.

[0166] The term "pharmaceutical excipient" refers to a pharmaceutical carrier, diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), or excipient that is administered with a therapeutic agent.

[0167] The pharmaceutical compositions of the present invention may include the antibodies and pharmaceutical excipients of the present invention. These pharmaceutical compositions may be included in kits, such as diagnostic kits.

[0168] As used herein, "pharmaceutical carrier" includes any and all physiologically compatible solvents, dispersion media, isotonic agents, and absorption delay agents. Pharmaceutical carriers suitable for this invention can be sterile liquids, such as water and oils, including those of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is a preferred carrier when administering pharmaceutical compositions intravenously. Saline solutions, aqueous dextran, and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions.

[0169] Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc. For information on the use and applications of excipients, see "Handbook of Pharmaceutical Excipients," 5th Edition, R.C. Rowe, P.J. Seskey, and S.O. Wen, Pharmaceutical Press, London, Chicago. The compositions may also contain small amounts of wetting agents or emulsifiers, or pH buffers. These compositions can be in the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, etc. Oral formulations may contain standard carriers such as pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, saccharin, etc.

[0170] This invention provides pharmaceutical compositions comprising one or more CD47-binding monoclonal antibodies or antigen-binding fragments thereof, nucleic acids of the present invention, vectors or host cells or immune conjugates or fusions. It should be understood that the anti-CD47 antibodies or antigen-binding fragments thereof, nucleic acids, vectors or host cells or immune conjugates or fusions or pharmaceutical compositions provided by this invention can be integrated with suitable pharmaceutical carriers, excipients and other reagents in a formulation for co-administration, thereby providing improved transfer, delivery, tolerability, etc.

[0171] Pharmaceutical formulations comprising the antiCD47 antibody described herein can be prepared by mixing the antiCD47 antibody of the present invention, or its antigen-binding fragment, having the desired purity, with one or more optional pharmaceutical excipients, preferably in the form of an aqueous solution or a lyophilized formulation. Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent Nos. 6,171,586 and WO2006 / 044908, the latter comprising a histidine-acetate buffer.

[0172] The pharmaceutical compositions or formulations of the present invention may also contain one or more other active ingredients required for the treatment of a specific disease, preferably those having complementary activities that do not adversely affect each other. For example, it is desirable to also contain other therapeutic agents. In some embodiments, the other therapeutic agents are chemotherapeutic agents, radiotherapy agents, cytokines, vaccines, other antibodies, immunomodulators, or other biological macromolecular drugs.

[0173] In some embodiments, the pharmaceutical compositions of the present invention further comprise a composition of a nucleic acid encoding an anti-CD47 antibody or an antigen-binding fragment thereof.

[0174] Method or use

[0175] In one aspect, the present invention provides a method for preventing, diagnosing, or treating CD47-related diseases in a subject. The method comprises administering to a patient in need an effective amount of the anti-CD47 antibody described herein or an antigen-binding fragment thereof, or an immunoconjugate or immunofusion thereof, or a pharmaceutical composition comprising therethe, or a nucleic acid, vector, or host cell described herein.

[0176] In one aspect, the present invention provides the use of an anti-CD47 antibody or an antigen-binding fragment thereof in the production or preparation of a medicament for the prevention, diagnosis or treatment of CD47-related diseases in a subject.

[0177] In one aspect, the anti-CD47 antibody and its antigen-binding fragment, and the pharmaceutical composition comprising the present invention, provided by the present invention, can be used as a therapeutic agent for the prevention or treatment of CD47-related diseases in subjects. For CD47-related diseases in subjects identified using standard methods, the anti-CD47 antibody and its antigen-binding fragment disclosed in this invention, and the pharmaceutical composition or immunoconjugate or immunofusion thereof, or the nucleic acid, vector, or host cell described herein, can be administered.

[0178] In some embodiments, the methods and uses described herein further include administering an effective amount of at least one additional therapeutic agent or treatment to the individual. In some embodiments, the therapeutic agent may be, for example, a chemotherapeutic agent, a radiotherapy agent, a cytokine, a vaccine, other antibodies, immunomodulators, or other biological macromolecular drugs. In some embodiments, the treatment may include surgery; radiotherapy, local irradiation, or focused irradiation, etc.

[0179] The aforementioned combination therapy includes combined administration (where two or more therapeutic agents are contained in the same or separate formulations) and separate administration, wherein the administration of the anti-CD47 antibody or its antigen-binding fragment of the present invention may occur before, simultaneously with, and / or after the administration of other therapeutic agents and / or adjuvants and / or modes of treatment.

[0180] In some embodiments, the CD47-related diseases described in this invention refer to diseases associated with abnormal CD47 expression, activity, and / or signaling in a subject, including but not limited to cancer. In some embodiments, CD47-related diseases are characterized by elevated levels or amounts of nucleic acids encoding CD47, or elevated CD47 expression, or elevated CD47 protein levels, or elevated activity, or enhanced active signaling.

[0181] In some implementations, treatment of the disease will benefit from inhibiting the levels of CD47 in nucleic acids or proteins, or from blocking the binding of CD47 to its ligands or CD47-mediated signal transduction.

[0182] In some embodiments, the subject may be a mammal, such as a primate, preferably a higher primate, such as a human (e.g., an individual suffering from or at risk of suffering from the diseases described herein). In one embodiment, the subject suffers from or is at risk of suffering from the diseases described herein (e.g., cancer). In some embodiments, the subject has received or has received other treatments, such as chemotherapy and / or radiation therapy.

[0183] In some embodiments, the cancers include various hematologic malignancies and solid tumors, as well as metastatic lesions. In one embodiment, examples of solid tumors include malignant tumors. The cancers can be in the early, intermediate, or late stages, or metastatic stages. Examples of the cancers include bladder cancer, pancreatic cancer, lymphoma, leukemia, multiple myeloma, (malignant) melanoma, leiomyosarcoma, leiomyosarcoma, glioma, glioblastoma, myeloma, endometrial cancer, kidney cancer, (benign) birthmark tumors, prostate cancer, thyroid cancer, cervical cancer, stomach cancer, and liver cancer. In some embodiments, the lymphomas are selected from Burkitt lymphoma, diffuse large cell lymphoma, or mantle cell lymphoma. In some embodiments, the leukemia is promyelocytic leukemia.

[0184] The antibodies or antigen-binding fragments of the present invention can be administered by any suitable route, including oral, parenteral, intrapulmonary, and intranasal administration, and, if local treatment is required, intralesional administration. Parenteral infusion includes intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Administration can be carried out by any suitable route, such as by injection, for example, intravenous or subcutaneous injection, depending in part on whether the administration is transient or long-term. Various dosing regimens are considered herein, including but not limited to single or multiple administrations at various time points, bolus administration, and pulsatile infusion.

[0185] The antibody or antigen-binding fragment of the present invention will be formulated and administered in accordance with good medical practice. It is not mandatory, but optionally, that the antibody is formulated with one or more agents currently used for the prevention or treatment of the stated disease. The effective amount of these other agents depends on the amount of antibody present in the formulation, the type of symptom or disease being treated, and other factors discussed above. For the prevention or treatment of disease, the appropriate dosage of the antibody or antigen-binding fragment of the present invention will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventative or therapeutic purposes, prior treatment, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The antibody is appropriately administered to the patient once or after a series of treatments.

[0186] In some embodiments, any anti-CD47 antibody or its antigen-binding fragment provided herein can be used to detect the presence of CD47 in a sample. In some embodiments, the detection method includes:

[0187] (a) Contacting the sample with the antibody or its antigen-binding fragment or conjugate or fusion compound provided in this invention; and

[0188] (b) Detect the formation of a complex between the antibody or its antigen-binding fragment or conjugate or fusion and the CD47 protein.

[0189] When used herein, the term "detection" includes both quantitative and qualitative detection. In some embodiments, the sample is blood, serum, or other liquid sample of biological origin. In some embodiments, the sample comprises cells or tissue. In some embodiments, the sample is derived from a lesion associated with hyperplastic or cancerous lesions.

[0190] In one embodiment, the antibodies of the present invention or their antigen-binding fragments can be used to diagnose CD47-related diseases, such as cancer, for example, to evaluate (e.g., monitor) the treatment or progression of the diseases described herein in an individual, their diagnosis, and / or staging. In some embodiments, labeled anti-CD47 antibodies or their antigen-binding fragments are provided. Labeling includes, but is not limited to, labels or portions that are directly detected (such as fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels), and portions that are indirectly detected, such as enzymes or ligands, for example, through enzymatic reactions or molecular interactions. In some embodiments, kits for diagnosing CD47-related diseases are provided herein, which contain the antibodies of the present invention or their antigen-binding fragments.

[0191] In some embodiments provided herein, the sample is obtained prior to treatment with an anti-CD47 antibody or its antigen-binding fragment. In some embodiments, the sample is obtained prior to treatment with other therapies. In some embodiments, the sample is obtained during or after treatment with other therapies.

[0192] This invention includes any combination of the specific embodiments described herein. It should be understood that although specific content and examples have been described to illustrate preferred embodiments of the invention, this is merely illustrative and for example purposes, and the invention also covers modifications to the preferred embodiments of the invention that will be obvious to those skilled in the art. For all purposes, all disclosures, patents, and patent applications cited herein, including in citations, are incorporated herein by reference in their entirety. Detailed Implementation

[0193] Example 1: Preparation and Screening of Hybridoma Antibodies

[0194] Anti-CD47 antibodies were obtained using hybridoma technology. Recombinant human CD47 extracellular domain-tagged protein CD47-Fc (ACROBiosystems, Cat: CD7-H5256) was used as the antigen to immunize mice. The recombinant CD47-Fc protein was mixed with complete or incomplete Freund's adjuvant (Sigma-Aldrich) and emulsified before being used to immunize SJL (Beijing Vital River Laboratory Animal Technology Co., Ltd.) and BALB / c (Yangzhou University Medical Center) mice. After one round of immunization (complete Freund's adjuvant) and two rounds of booster immunization (incomplete Freund's adjuvant), blood was collected after each booster immunization. The binding activity of the mouse serum to the recombinant human CD47-Fc (ACROBiosystems, Cat: CD7-H5256) protein was detected by ELISA, and the binding titer of the mouse serum to CHO cells (GenScript construction) overexpressing human CD47 was detected by flow cytometry (FACS). Splenic cells from mice with high serum titers were fused with the myeloma cell line SP2 / 0 (ATCC). Four days prior to fusion, recombinant CD47-Fc protein, containing the extracellular domain of human CD47, was intraperitoneally injected into mice to enhance immunity. On the day of fusion, mice were euthanized, and mouse spleen cells were homogenized to obtain a single-cell suspension. Mouse spleen cells were fused with the mouse myeloma cell line SP2 / 0 (3:1) using an electrofusion apparatus. The fused cells were resuspended in HAT (hypoxanthine, aminopterin, and thymidine deoxyribonucleoside, GIBCO, Cat: 21060016) medium to screen for successfully fused hybridoma cells. The supernatant of the hybridoma cells was collected, and hybridoma cells secreting antibodies specifically binding to human CD47 were screened using two rounds of ELISA. Subsequently, CD47-related functional screening experiments (e.g., specificity for binding to CD47 in humans or cynomolgus monkeys; lack of erythrocyte agglutination activity; and promotion of macrophage phagocytosis of tumor cells) were used to identify the activity of hybridoma secretory supernatant. Positive hybridoma clones underwent single or multiple rounds of subcloning to obtain monoclonal clones. After screening, 125G4A4 was the finally selected hybridoma clone.

[0195] Candidate hybridoma cells 125G4A4 were cultured for 7-10 days. The supernatant was collected, centrifuged, and filtered to remove cells and debris. The supernatant was passed through a Protein A purification column (GenScript), cleaned and equilibrated with a buffer containing 0.05M Tris and 1.5M NaCl (pH 8.0), eluted with 0.1M sodium citrate (pH 3.5), and immediately neutralized with 1 / 9 volume of 1M Tris-HCl (pH 9), followed by dialyzing with PBS buffer. The resulting hybridoma antibody 125G4A4 was used for further characterization.

[0196] 1.1 FACS detection of antibody binding activity to CHO-K1 cells overexpressing human CD47 protein

[0197] Human CD47 protein (NCBI accession number: NP_001768.1) was overexpressed in the hamster ovary cell line CHO-K1 to establish a CHO-K1 cell line overexpressing human CD47 protein. These cells were co-incubated with serially diluted antibody 125G4A4 and control antibody C0774CK230-C (i.e., Hu5F9) (maximum concentration 300 nM, three-fold dilution, 12 concentration points) at 4°C for 50 minutes. The cells were washed twice with ice-cold PBS, and iFluor647-labeled goat anti-mouse IgG (H+L) antibody (Genscript) was added, followed by incubation at 4°C in the dark for 40 minutes. After washing the cells twice with ice-cold PBS, fluorescence signals were detected using a Calibur (BDBiosciences) flow cytometer. The concentration-dependent curve was fitted using GraphPad based on the mean fluorescence intensity (MFI), and EC was calculated. 50 As shown in Table 1, the final hybridoma antibody 125G4A4 exhibits high binding activity to CHO-K1 overexpressing human CD47 protein, EC... 50 It is 0.22 nM.

[0198] 1.2 FACS detection of antibody binding activity to CD47 on tumor cell line surface

[0199] Raji cells, a human Burkitt lymphoma cell line, endogenously express human CD47 on their surface. Antibody 125G4A4 and control antibody Hu5F9 were serially diluted in PBS containing 2% fetal bovine serum (FBS, Gibco, Cat: 10100147) (maximum concentration 46.3 nM, three-fold dilution, 8 concentration spots in total). The diluted antibody was then mixed with Raji cells (purchased from ATCC) (5*10 cells per well). 5 After mixing (number of cells), the mixture was incubated at 4°C for 1 hour. The cells were then washed three times with PBS containing 2% fetal bovine serum (FBS), and PE-labeled mouse anti-human IgG Fc antibody (Biolegend, Cat:409304) was added. The mixture was then incubated at 4°C in the dark for 1 hour. After washing the cells three times with PBS containing 2% fetal bovine serum (FBS), fluorescence signals were detected using a CantoII (BD Biosciences) flow cytometer. A concentration-dependent curve was fitted using GraphPad based on the mean fluorescence intensity (MFI), and EC50 was calculated. 50 As shown in Table 1, hybridoma antibody 125G4A4 exhibits binding activity with Raji cells, EC... 50 It is 0.84±0.02nM.

[0200] 1.3 Anti-CD47 antibody blocks the interaction between human CD47 and SIRPα

[0201] The ability of 125G4A4 to block the binding of human CD47 to SIRPα was detected using ELISA. Human CD47 extracellular fragment and recombinant human IgG Fc-terminal protein hCD47-Fc (ACROBiosystems, Cat:CD7-H5256) were coated onto 96-well plates and incubated overnight at 4°C. After washing three times with PBST (PBS containing 0.5% Tween-20), the plates were blocked with PBST containing 1% BSA for 2 hours. After washing three times with PBST, a mixture of serially diluted antibody 125G4A4, control antibody Hu5F9 (maximum concentration 66.7 nM, three-fold dilution, 8 concentration points), and SIRPα-His recombinant protein (ACROBiosystems, Cat:SIA-5225) at a final concentration of 2.5 μg / ml was added and incubated at room temperature for 1 hour. Wash the plate three times with PBST, then add horseradish peroxidase-labeled goat anti-His-tag secondary antibody (CWBIO, Cat: CW0285M) to detect SIRPα captured by coated CD47. Incubate the 96-well plate at 37°C for 30 minutes, then wash five times with PBST. Add TMD (Surmodics, Cat: TMBW-1000-01) chromogenic buffer and incubate in the dark for 15 minutes. Stop the chromogenic reaction by adding 2N H2SO4. Read the OD values ​​using a microplate reader. 450 The absorbance value reflects the amount of SIRPα bound to CD47. A concentration-dependent curve was fitted using Graphpad, and the IC50 value for the anti-CD47 antibody to block the binding of CD47 to SIRPα was calculated. 50 As shown in Table 1, 125G4A4 can effectively block the interaction between CD47 and SIRPα, IC 50 It is 3.06 nM.

[0202] 1.4 Detection of anti-CD47 antibody-induced human erythrocyte agglutination activity

[0203] It is known that most anti-CD47 antibodies in the prior art have the property of inducing erythrocyte agglutination. This property is generally considered to be closely related to the side effects such as anemia that occur with therapeutic anti-CD47 antibodies. Therefore, we evaluated the anti-CD47 antibody of this invention through an in vitro erythrocyte agglutination assay to screen for antibodies without erythrocyte agglutination properties. The specific method is as follows: Fresh human blood was collected from healthy donors, washed five times with PBS, and diluted to a suspension containing 10% human erythrocytes. The erythrocyte suspension was mixed with experimental antibodies (antibody 125G4A4 and control antibody Hu5F9, highest concentration 667 nM, three-fold dilution, a total of 12 concentration points) and added to a round-bottom 96-well plate. After incubation at room temperature for 16 hours, photographs were taken, and the results were determined based on the cell behavior in the wells. If erythrocyte agglutination occurred, the cells would spread out in a mesh-like pattern, presenting a large sheet-like cell layer in the well, with a diameter larger than that of the negative control well; conversely, if no agglutination occurred, the erythrocytes would deposit at the bottom of the well, resulting in small, dot-like cell clusters in the well. 125G4A4 did not exhibit significant erythrocyte agglutination characteristics in this experiment.

[0204] 1.5 Detection of the effect of anti-CD47 antibody on the phagocytic activity of human macrophages on tumor cells

[0205] The ability of the antibody 125G4A4 of this invention to promote the phagocytosis of tumor cells by macrophages was detected using a flow cytometry-based assay. Fresh blood was collected from healthy donors and peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Cat: 17-1440-02). Mononuclear cells were further isolated using a human total mononuclear cell isolation kit (Miltenyi Biotec, Cat: 130-096-537), and cultured with macrophage colony-stimulating factor (M-CSF, R&D Systems, Cat: 216-MC) for 7 consecutive days to induce differentiation into macrophages. On the day of the phagocytosis assay, the differentiated macrophages were starved in serum-free culture medium for 2 hours. Simultaneously, target tumor cells (Raji) were fluorescently labeled according to the labeling procedure recommended in the CFSE (eBioscience, Cat: 65-0850-85) instruction manual. Labeled tumor cells and macrophages were mixed at a ratio of 4:1, and the experimental antibody at the target concentration was added and incubated at 37°C for 2 hours. The cells were then washed twice with PBS, digested with trypsin (Gibco, Cat: 25200072), and incubated with APC-labeled anti-CD14 antibody (Biolegend, Cat: 325608) on ice for 30 minutes in PBS containing 2% fetal bovine serum, protected from light. The cells were washed twice and analyzed by flow cytometry. The percentage of CFSE-positive cells in the CD14-positive macrophage population was calculated. As shown in Table 1, 125G4A4 effectively promoted the phagocytic effect of macrophages on tumor cells.

[0206] Table 1. Identification of the activity and function of hybridoma antibody 125G4A4

[0207]

[0208] Example 2: Humanization of Hybridoma Antibodies

[0209] 2.1 Determination of the variable region sequence of hybridoma antibody

[0210] Using hybridoma sequencing, cells of hybridoma clone 125G4A4 were expanded and cultured, and total RNA was extracted using TRIzol (purchased from Ambio). This RNA was then reverse transcribed into DNA using antibody-specific primers (Takara, PrimerScript 1). stThe Strand cDNA Synthesis Kit was used to amplify the gene fragment encoding the V-region of mouse immunoglobulin using antibody-specific primers. Sequence analysis yielded the hybridoma antibody variable region sequence. The amino acid sequences of the heavy chain variable region and the light chain variable region of the 125G4A4 antibody are shown in SEQ.ID No.:1 and 2, respectively, and the nucleotide sequences are shown in SEQ.ID No.:19 and 20, respectively.

[0211] 2.2 Construction and Expression of Chimeric Antibodies

[0212] Based on the CD47 mechanism of action, in this specific embodiment of the invention, the constant region of human IgG4 (S228P) is used as the heavy chain constant region of the antibody, and the constant region of the human light chain κ chain is used as the light chain constant region of the antibody. Mutating serine at position 228 of the IgG4 core hinge region to proline (S228P) enhances disulfide bond linkage in the core hinge region, reduces IgG4 Fab arm exchange, and significantly reduces the formation of half-molecules. After the heavy and light chain constant region genes are synthesized, the heavy and light chain variable region genes are homologously recombinated into the vector via EcoRI and BamHI double digestion of the PTT5 enzyme. After correct sequencing, the antibody heavy and light chains are co-transfected into HEK293 cells at a molar ratio of 1.5:1. After culturing for 120 hours, the supernatant is collected by centrifugation and purified to obtain the chimeric antibody.

[0213] Before designing humanized antibodies, it is necessary to mutate some posttranslational modification (PTM) sites in the CDR region to avoid affecting protein conformation and thus its function. PTM analysis identified two PTM sites in the CDR of 125G4A4: an NSS glycosylation site in the heavy chain and a DG isomerization site in the light chain. The NSS glycosylation site and the DG isomerization site were mutated to QSS and EG, respectively. The mutated chimeric antibody purified according to this example was named Ch-125G4-m35. The amino acid sequences of the heavy chain variable region and the light chain variable region of the Ch-125G4-m35 antibody are shown in SEQ.ID No.:3 and 4, respectively.

[0214] 2.3 Humanization Design of Chimeric Antibodies

[0215] The variable region sequence of the chimeric antibody 125G4A4m was compared with the PDB_Antibody database using BLAST. The human backbone sequence with the highest similarity was selected for humanization: the 125G4A4m heavy chain variable region showed high sequence homology with human germline IGHV1-69, and the light chain variable region showed high sequence homology with human germline IGKV1-16. The amino acid sequence and precise boundaries of the variable region CDR were then defined using the Kabat assignment system. Subsequently, the CDR segment of the mouse antibody variable region was grafted into the human backbone sequence to achieve antibody humanization.

[0216] To maintain antibody activity, computer simulation technology can be used to analyze the variable region and its surrounding framework amino acid sequences through molecular docking, examining their spatial binding mode. By calculating electrostatic forces, van der Waals forces, hydrophilicity / hydrophobicity, and entropy, key amino acid individuals in each candidate antibody gene sequence that can interact with CD47 and maintain the spatial framework are analyzed. These individuals are then grafted back into the selected human antibody gene framework, and the amino acid sites in the framework region that must be retained are marked, leading to the synthesis of humanized antibodies. Some key sites in the antibody framework region are reverted to the chimeric antibody Ch-125G4-m35 antibody framework region sequence. Based on the number and arrangement of reverted mutations, multiple different humanized heavy chain variable regions (SEQ.ID No.:5, SEQ.ID No.:6, SEQ.ID No.:7) and light chain variable regions (SEQ.ID No.:8, SEQ.ID No.:9, SEQ.ID No.:10) are designed (see Table 2). The humanized antibody Hu-125G4A4-48, which was finally determined in this invention, was named HMA02h14-48 in subsequent experiments. The amino acid sequences of the heavy chain variable region and the light chain variable region of this antibody are shown in SEQ.IDNo.:7 and 8, respectively.

[0217] Table 2. Number and arrangement of 125G4A4m heavy and light chain reversion mutations

[0218]

[0219]

[0220] Table 3. Amino acid sequence of anti-CD47 antibody

[0221] Antibody Heavy chain variable region sequence Light chain variable region sequence 125G4A4 SEQ ID No.:1 SEQ ID No.:2 ch-125G4-m35 SEQ ID No.:3 SEQ ID No.:4 Hu-125G4A4m-43 SEQ ID No.:6 SEQ ID No.:9 Hu-125G4A4m-44 SEQ ID No.:6 SEQ ID No.:10 Hu-125G4A4m-45 SEQ ID No.:5 SEQ ID No.:8 Hu-125G4A4m-46 SEQ ID No.:5 SEQ ID No.:9 Hu-125G4A4m-47 SEQ ID No.:5 SEQ ID No.:10 Hu-125G4A4m-48 SEQ ID No.:7 SEQ ID No.:8 Hu-125G4A4m-49 SEQ ID No.:7 SEQ ID No.:9 Hu-125G4A4m-50 SEQ ID No.:7 SEQ ID No.:10

[0222] Table 4. CDR amino acid sequence of anti-CD47 antibody (Kabat definition)

[0223]

[0224] 2.4 Expression of humanized antibodies

[0225] The humanized heavy and light chain variable region DNA fragments were amplified and cloned into a vector containing the constant region for expressing human antibodies to construct an antibody-expressing plasmid (pCDNA3.4, purchased from Thermo Cat#A14697). The expression vectors of the heavy and light chains were co-transfected into Expire293 cells (Thermo Cat#A14525) and cultured at 37°C for 6 days. The supernatant was collected and purified by Protein A affinity according to the aforementioned method to obtain the recombinant antibody for further antibody characterization. The humanized antibody was the IgG4S228P (IgG4P) subtype.

[0226] Example 3: Screening of humanized antibodies

[0227] Highly active humanized antibodies were screened by detecting the binding ability of humanized antibodies to cynomolgus monkey B cells, the ability of human macrophages to phagocytose tumor cells, and the agglutination ability of erythrocytes.

[0228] The binding ability of humanized antibodies to monkey B cells was detected by flow cytometry. The binding of 125G4A4 humanized antibodies to CD47 on the surface of cynomolgus monkey B cells was measured. The specific method was as follows: Peripheral blood mononuclear cells (PBMCs) were obtained from cynomolgus monkey blood (provided by Shanghai Yinuosi Biotechnology Co., Ltd.) by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Cat: 17-1440-02). PBMCs were incubated with 125G4A4 humanized antibodies or isotype (IgG4P) in PBS containing 2% fetal bovine serum at 4°C for 30 minutes. The cells were then washed three times and incubated with a secondary antibody (PE-labeled mouse anti-human IgG Fc antibody, Biolegend, Cat: 409304) in PBS containing 2% fetal bovine serum at 4°C in the dark for 30 minutes. The cells were washed three times and analyzed by flow cytometry. Using an anti-human CD20 antibody (Brilliant Violet 421) that cross-reacts with cynomolgus monkeys. TM B cells were labeled with anti-human CD20 (Biolegend, Cat: 302330) and their mean fluorescence intensity (MFI) was obtained by flow cytometry on a Canto II (BD Biosciences) instrument.

[0229] The ability of macrophages to phagocytose tumor cells and the ability of erythrocytes to agglutinate were detected according to the methods described in Examples 1.5 and 1.4, respectively.

[0230] The results are shown in Table 5. Under the tested concentration conditions, the 125G4A4 humanized antibody series bound to CD47 expressed on cynomolgus monkey B cells, promoting the phagocytic ability of macrophages against Raji tumor cells. Among them, Hu-125G4A4m-48 showed the strongest phagocytic efficiency at 33 nM. Its other activities were similar to the chimeric antibody Ch-125G4m-m35, with fewer recurrent mutations. Therefore, it was selected for further testing, and the subsequent test was named HMA02h14-48.

[0231] Table 5. In vitro activity assays of anti-CD47 humanized antibody series.

[0232]

[0233]

[0234] Example 4: FACS detection of the binding ability of HMA02h14-48 to tumor cells

[0235] Raji cells, a human Burkitt lymphoma cell line (Shanghai Institute of Life Sciences, SIBS, CCL-86) TM / ATCC), human diffuse large cell lymphoma Toledo cells ( CRL-2631 TM and human mantle cell lymphoma REC-1 cells ( CRL-3004 TM The tumor cells expressed endogenous human CD47 on their surface. The binding of the humanized antibody HMA02h14-48 to CD47 on the surface of the tumor cells was detected by flow cytometry using the detection method described in Example 1.2 above. The highest antibody concentration was 667 nM, and serial dilutions were performed, testing a total of 8 concentrations.

[0236] The results are as follows Figure 1-3 As shown, both HMA02h14-48 and Hu5F9 bind to CD47 expressed on the surface of Raji, Toledo, and REC-1 tumor cells. HMA02h14-48 exhibits a higher maximum fluorescence intensity at the plateau phase than Hu5F9, and its EC50... 50 The maximum fluorescence intensity is shown in Table 6.

[0237] Table 6. Binding activity of antibody HMA02h14-48 to CD47 on the surface of tumor cells.

[0238]

[0239] The negative isotype antibody used in this embodiment and other embodiments is human IgG4P, which was purchased from Shanghai Ruizhi Chemical Research Co., Ltd.

[0240] Example 5: Biacore detection of the affinity between antibody HMA02h14-48 and human CD47.

[0241] Biacore determines binding kinetic parameters by measuring surface plasmon resonance (SPR). This technique detects the microscopic rate constants of antibody-antigen binding (ka) and dissociation (kd), and calculates the antibody-antigen affinity. The Biacore instrument (Biacore T200) and reagents were purchased from GE Healthcare. Anti-human Fc antibodies were immobilized on a sensor chip CM5. Purified antibodies (HMA02H14-48 and Hu5F9) were diluted in mobile phase buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20, pH 7.4) and flowed through the CM5 chip coated with anti-human Fc antibodies. Then, serially diluted human CD47-His (ACROBiosystems, Cat: CD7-H5227) fusion protein was passed through a detection chip to measure antigen-antibody binding, followed by the passage of mobile phase buffer through the chip to detect antigen-antibody dissociation. Binding and dissociation signal data for antigen and antibody at different concentrations were collected, and the affinity between antigen and antibody was calculated using a 1:1 Langmuir model.

[0242] The results are shown in Table 7. HMA02h14-48 binds with high affinity to human CD47, K D The value is 7.77E-10(M).

[0243] Table 7. Kinetic constants for Biacore detection of humanized antibody binding to human CD47.

[0244]

[0245] Example 6: ELISA detection of the activity of HMA02h14-48 in blocking the interaction between human CD47 and SIRPα.

[0246] As described in Example 1.3 above, the ability of HMA02h14-48 to block the interaction between human CD47 and SIRPα was detected using ELISA. The highest antibody concentration was 67 nM, and serial dilutions were performed, with a total of 8 concentrations tested.

[0247] The results are as follows Figure 4 As shown, the antibody HMA02h14-48 of this invention blocks the interaction between human CD47 and SIRPα, IC50. 50 =1.58nM.

[0248] Example 7: Effect of HMA02h14-48 on the phagocytic activity of human macrophages against tumor cells

[0249] Following the method described in Example 1.5, the phagocytic effect of HMA02h14-48 on human macrophages against human Burkitt lymphoma cell line Raji cells, human diffuse large cell lymphoma Toledo cells, human mantle cell lymphoma REC-1 cells, and human promyelocytic leukemia cell line HL-60 cells was examined. The highest antibody concentration was 100 μg / mL, and serial dilutions were performed, with a total of eight concentrations tested.

[0250] The results showed that, compared with the control antibodies Hu5F9 and SRF231, HMA02h14-48 promoted the phagocytosis of human Burkitt lymphoma cell line Raji by macrophages, with a maximum phagocytic efficiency of 36.5%. The phagocytic rate at different concentrations (0.1–100 μg / ml) was higher than that of Hu5F9 and SRF231. HMA02h14-48 achieved a maximum phagocytic efficiency of 84.6% against human mantle cell lymphoma REC-1, and maintained a phagocytic rate of approximately 70% even at a low concentration of 0.1 μg / ml, which was higher than that of Hu5F9 and SRF231. HMA02h14-48 promoted the phagocytosis of Toledo cells by macrophages, with a phagocytic rate of 94.2%. HMA02h14-48 also promoted the phagocytosis of HL-60 tumor cells by macrophages, with a maximum phagocytic efficiency of 65%.

[0251] Table 8. Effect of antibody HMA02h14-48 on enhancing the phagocytosis of tumor cells by human macrophages.

[0252]

[0253] Example 8: Detection of the effect of HMA02h14-48 on the in vitro agglutination activity of erythrocytes

[0254] Human erythrocytes were diluted to 10% in PBS and incubated with the added CD47 antibody in 96-well round-bottom plates at room temperature for 16 hours. The presence of unprecipitated erythrocytes is evidence of hemagglutination; compared to the white dots formed by the precipitation of unprecipitated erythrocytes, the unprecipitated erythrocytes appear as a network with a larger area than the negative isotype control antibody (see [link to negative isotype control antibody]). Figure 9 The test results of negative isotype control antibodies are used as the normal standard.

[0255] As described in Example 1.4 above, the antibody HMA0214-48 was tested for erythrocyte agglutination. The highest antibody concentration was 667 nM, and it was serially diluted, with a total of 12 concentrations tested.

[0256] The results are as follows Figure 9As shown, CD47 antibody Hu5F9 caused significant agglutination of erythrocytes at concentrations equal to or higher than 0.9 nM, while antibody HMA02h14-48 in this invention did not cause significant agglutination of human erythrocytes in vitro at different concentrations ranging from 0.004 to 667 nM.

[0257] Example 9: FACS detection of the binding ability of HMA02h14-48 to human erythrocytes

[0258] In existing technologies, therapeutic anti-CD47 antibodies frequently cause anemia as a side effect during clinical application. It is generally believed that the binding of anti-CD47 antibodies to CD47 on the surface of red blood cells, leading to phagocytosis of red blood cells by macrophages, may be another major cause of anemia. In this invention, we used flow cytometry to detect the binding ability of HMA02h14-48 to human red blood cells to assess the risk of the antibody. Specifically, red blood cells derived from healthy donors were incubated with diluted HMA02h14-48 (maximum concentration 667 nM, 8 test concentrations) in PBS containing 2% fetal bovine serum at 4°C for 30 minutes. The cells were then washed three times and incubated with a secondary antibody (PE-labeled mouse anti-human IgG Fc antibody, Biolegend, Cat:409304) in PBS containing 2% fetal bovine serum at 4°C in the dark for 30 minutes. Cells were washed three times with PBS containing 2% fetal bovine serum (FBS), and fluorescence signals were detected using a Canto II (BD Biosciences) flow cytometer. Based on the mean fluorescence intensity (MFI), a concentration-dependent curve was fitted using GraphPad, and EC50 was calculated. 50 .

[0259] The results are as follows Figure 10 As shown, the maximum average fluorescence intensity of HMA02h14-48 binding to CD47 on the surface of human erythrocytes was lower than that of the control antibody Hu5F9. Its EC50... 50 The maximum average fluorescence intensity is shown in Table 9.

[0260] Table 9. Binding activity of antibody HMA02h14-48 to CD47 on the surface of human erythrocytes.

[0261]

[0262] Example 10: Inhibition of Toledo tumor growth by humanized antibody HMA02h14-48

[0263] Objective: To establish a Toledo subcutaneous tumor model in NOD-Scid mice and to study the antitumor activity of the antibody of this invention.

[0264] Methods: Human diffuse large cell lymphoma cells Toledo were cultured in RPMI 1640 medium containing 10% fetal bovine serum. CRL-2631 TM Tumor cells were suspended in RPMI 1640 at a concentration of 1×10⁻⁶. 7 Cells / mouse dose were implanted subcutaneously in the right rib area of ​​male NOD-Scid mice (Shanghai Lingchang Biotechnology Co., Ltd.).

[0265] Fifteen days after tumor cell inoculation, mice were randomly divided into 6 groups according to tumor volume. Hu5F9 and HMA02h14-48 antibodies were diluted with PBS and administered at a dose of 10 mg / kg according to the regimens shown in Table 10. The negative isotype control antibody IgG4P was purchased from Shanghai Ruizhi Chemical Research Co., Ltd.

[0266] Table 10. Dosing regimens for Hu5F9 and HMA02h14-48

[0267]

[0268]

[0269] Note: The day of grouping is designated as day 0, and the day after grouping is designated as day 1 for drug administration.

[0270] Tumor volume (tumor volume = 0.5 × major axis × minor axis²) and mouse body weight were measured periodically. Student's t-test in Excel was used for statistical analysis of changes in tumor volume and body weight; p < 0.05 was considered statistically significant. The tumor regression rate in each antibody treatment group after drug administration was calculated.

[0271] The formula for calculating the tumor regression rate in each treatment group is: [(D0 mean tumor volume - D...] t [Mean tumor volume (D0) / (Mean tumor volume)] × 100%.

[0272] The formula for calculating the relative body weight of mice is: (body weight of mice on the day of measurement / body weight of mice at the time of grouping) × 100%.

[0273] result:

[0274] The experimental results are shown in Table 11 and Figure 11 As shown.

[0275] In the Isotype control antibody group, tumor growth was good, while in the other treatment groups, subcutaneous tumors gradually shrank from their initial size after antibody administration, eventually disappearing completely. Specifically, all doses of the Hu5F9 and HMA02h14-48 antibody groups achieved complete tumor disappearance (100% regression rate) by day 11, showing a highly significant difference in tumor volume change compared to the control antibody group. Furthermore, even after drug withdrawal, continued observation until day 67 showed no signs of tumor regrowth. In addition, the animals in all HMA02h14-48 dose groups were in good condition, with no significant difference in body weight on day 21 compared to pre-treatment levels. In the high-dose Hu5F9 group, body weight decreased by approximately 5% on day 21 compared to day 0, but this was not statistically significant compared to the initial body weight (p>0.05); while the low-dose group showed no weight loss, suggesting a dose-response relationship between Hu5F9 and body weight.

[0276] Based on the above data, both Hu5F9 and HMA02h14-48 antibody treatments have extremely significant anti-tumor effects. A single dose of 10 mg / kg can completely eliminate the tumor, and the effect lasts for a long time.

[0277] Table 11 Effects of Hu5F9 and HMA02h014-48 on the growth of Toledo subcutaneous xenografts

[0278]

[0279]

[0280] Note: ** indicates p<0.01; the numbers in parentheses represent the tumor regression rate.

[0281] Example 11: Inhibition of REC-1 tumor growth by humanized antibody HMA02h14-48

[0282] Objective: To establish a REC-1 subcutaneous tumor model in NOD-Scid mice and to study the antitumor activity of the antibody of this invention.

[0283] Methods: Human mantle cell lymphoma cells REC-1 were cultured in RPMI 1640 medium containing 10% fetal bovine serum. CRL-3004 TM Tumor cells were suspended in RPMI 1640 at a concentration of 5 × 10⁻⁶. 6 Cells / mouse dose were implanted subcutaneously in the right rib area of ​​male NOD-Scid mice (Shanghai Lingchang Biotechnology Co., Ltd.).

[0284] Eleven days after tumor cell inoculation, mice were randomly divided into 5 groups according to tumor volume. Hu5F9 and HMA02h14-48 antibodies were diluted with PBS and administered according to the regimens shown in Table 12. Hu5F9 antibody was prepared by GenScript, and HMA02h14-48 antibody was prepared according to the method in Example 2. The isotype control antibody IgG4p was purchased from Shanghai Ruizhi Chemical Research Co., Ltd.

[0285] Table 12 Dosing regimens for Hu5F9 and HMA02h14-48

[0286]

[0287] Note: The day of grouping is designated as day 0, and the day after grouping is designated as day 1 for drug administration.

[0288] Regularly measure tumor volume (tumor volume = 0.5 × major axis × minor axis). 2 (1) Mouse body weight. The tumor inhibition rate and regression rate in the antibody treatment group were statistically analyzed on day 12 after drug administration.

[0289] The tumor inhibition rate was calculated using the formula: [(mean change in tumor volume in the control group - mean change in tumor volume in the treatment group) / mean change in tumor volume in the control group] × 100%. Statistical analysis of tumor volume change and body weight was performed using the Student t-test in Excel software; p < 0.05 was considered statistically significant.

[0290] The formula for calculating the tumor regression rate in each treatment group is: [(average tumor volume at D0 - average tumor volume at Dt) / average tumor volume at D0] × 100%.

[0291] The formula for calculating the relative body weight of mice is: (body weight of mice on the day of measurement / body weight of mice at the time of grouping) × 100%.

[0292] result:

[0293] The experimental results are shown in Table 13 and Figure 12 As shown.

[0294] Twelve days after administration, compared with the Isotype group, the Hu5F9 antibody at a single dose of 3 mg / kg showed an inhibition rate of 16.7% on tumor growth (p>0.05); the HMA02h14-48 antibody at single doses of 1 mg / kg, 3 mg / kg, and 10 mg / kg showed inhibition rates of 3.8% (p>0.05), 54.7% (p<0.01), and 107.2% (p<0.001), respectively. The high-dose HMA02h14-48 antibody group achieved complete tumor disappearance (100% regression rate) by day 10. Furthermore, no significant differences in relative body weight were observed among the antibody treatment groups.

[0295] Based on the above data, in the REC-1 model, HMA02h14-48 antibody treatment is dose-dependent, and a single dose of 10 mg / kg can completely eliminate the tumor.

[0296] Table 13 Effects of Hu5F9 and HMA02h14-48 on the growth of REC-1 subcutaneous xenografts

[0297]

[0298] Note: ** indicates p<0.01; the numbers in parentheses represent the tumor regression rate.

[0299] The sequence of the present invention:

[0300]

[0301] .

Claims

1. An isolated anti-CD47 antibody or its antigen-binding fragment, comprising a heavy chain variable region VH and a light chain variable region VL, wherein the heavy chain variable region VH comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region VL comprises LCDR1, LCDR2, and LCDR3, wherein... (1). The HCDR1, HCDR2 and HCDR3 are, in order, the HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:1, and the LCDR1, LCDR2 and LCDR3 are, in order, the LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:2; (2). The HCDR1, HCDR2 and HCDR3 are, in order, the HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:3, and the LCDR1, LCDR2 and LCDR3 are, in order, the LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:4; (3). The HCDR1, HCDR2 and HCDR3 are, in turn, the HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:5, and the LCDR1, LCDR2 and LCDR3 are, in turn, the LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:8, 9 or 10. (4). The HCDR1, HCDR2, and HCDR3 are, in sequence, the HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO:6, and the LCDR1, LCDR2, and LCDR3 are, in sequence, the LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO:9 or 10; or (5). The HCDR1, HCDR2 and HCDR3 are, in turn, the HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:7, and the LCDR1, LCDR2 and LCDR3 are, in turn, the LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:8, 9 or 10.

2. An isolated anti-CD47 antibody or its antigen-binding fragment, comprising heavy chain complementarity-determining regions 1 (HCDR1), HCDR2, and HCDR3, and light chain complementarity-determining regions 1 (LCDR1), LCDR2, and LCDR3, wherein: (1) HCDR1 is composed of the amino acid sequence shown in SEQ ID NO: 11, HCDR2 is composed of the amino acid sequence shown in SEQ ID NO: 12, and HCDR3 is composed of the amino acid sequence shown in SEQ ID NO: 17; and (2) The LCDR1 is composed of the amino acid sequence shown in SEQ ID NO:14, the LCDR2 is composed of the amino acid sequence shown in SEQ ID NO:18, and the LCDR3 is composed of the amino acid sequence shown in SEQ ID NO:

16.

3. The antibody or antigen-binding fragment thereof as described in claim 1, comprising: (1) The heavy chain variable region (VH) comprising an amino acid sequence identical to or having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO: 1, 3, 5, 6 or 7; and (2) Light chain variable region (VL) containing an amino acid sequence that is identical to or has at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO: 2, 4, 8, 9 or 10.

4. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein... (1) VH contains the amino acid sequence shown in SEQ ID NO:1; and VL contains the amino acid sequence shown in SEQ ID NO:2; (2) VH contains the amino acid sequence shown in SEQ ID NO:3; and VL contains the amino acid sequence shown in SEQ ID NO:4; (3) VH contains the amino acid sequence shown in SEQ ID NO:5; and VL contains the amino acid sequence shown in SEQ ID NO:8, 9 or 10; (4) VH contains the amino acid sequence shown in SEQ ID NO:6; and VL contains the amino acid sequence shown in SEQ ID NO:9 or 10; or (5) VH contains the amino acid sequence shown in SEQ ID NO:7; and VL contains the amino acid sequence shown in SEQ ID NO:8, 9 or 10.

5. The antibody or antigen-binding fragment thereof as claimed in claim 4, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein... (1) VH consists of the amino acid sequence shown in SEQ ID NO:1; and VL consists of the amino acid sequence shown in SEQ ID NO:2; (2) VH consists of the amino acid sequence shown in SEQ ID NO:3; and VL consists of the amino acid sequence shown in SEQ ID NO:4; (3) VH consists of the amino acid sequence shown in SEQ ID NO:5; and VL consists of the amino acid sequence shown in SEQ ID NO:8, 9 or 10; (4) VH consists of the amino acid sequence shown in SEQ ID NO:6; and VL consists of the amino acid sequence shown in SEQ ID NO:9 or 10; or (5) VH consists of the amino acid sequence shown in SEQ ID NO:7; and VL consists of the amino acid sequence shown in SEQ ID NO:8, 9 or 10.

6. The antibody or antigen-binding fragment thereof as claimed in claim 4, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence shown in SEQ ID NO: 7, and the VL comprises the amino acid sequence shown in SEQ ID NO:

8.

7. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3 and 5-6, comprising a heavy chain constant region.

8. The antibody or antigen-binding fragment thereof as claimed in claim 7, wherein the heavy chain constant region is a human IgG1 constant region, a human IgG1™ constant region, a human IgG4 constant region, or a human IgG4P constant region.

9. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3, 5-6 and 8, comprising a light chain constant region.

10. The antibody or antigen-binding fragment thereof as claimed in claim 9, wherein the light chain constant region is the human light chain κ chain constant region.

11. The antibody or antigen-binding fragment thereof as described in any one of claims 1-3, 5-6, 8 and 10, wherein it is a humanized antibody.

12. The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-3, 5-6, 8 and 10, wherein it is a full-length antibody, Fab, Fab', Fab'-SH, F(ab')2, scFv or a multispecific antibody.

13. The antibody or antigen-binding fragment thereof as claimed in claim 12, wherein the multispecific antibody is a bispecific antibody.

14. An isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof as described in any one of claims 1-13.

15. A recombinant vector or expression vector comprising one or more nucleic acids as described in claim 14, wherein the vector is adapted for recombinant production of an antibody or antigen-binding fragment thereof as described in any one of claims 1-13.

16. A host cell comprising one or more recombinant vectors or expression vectors as described in claim 15.

17. A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-13, a nucleic acid as described in claim 14, a vector as described in claim 15, or a host cell as described in claim 16.

18. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient.

19. Use of the antibody or antigen-binding fragment thereof as described in any one of claims 1-13, the nucleic acid as described in claim 14, the vector as described in claim 15, the host cell as described in claim 16, or the pharmaceutical composition as described in claim 17 in the preparation of a medicament for treating cancer, wherein the cancer is selected from pancreatic cancer, lymphoma, leukemia, multiple myeloma, glioblastoma, and gastric cancer.

20. The use as described in claim 19, wherein the lymphoma is selected from Burkitt lymphoma, diffuse large cell lymphoma, or mantle cell lymphoma.

21. The use as claimed in claim 19, wherein the leukemia is promyelocytic leukemia.

22. The use as claimed in any one of claims 19-21, wherein the cancer is associated with abnormal CD47 expression, activity and / or signaling.

23. The use according to any one of claims 19-21, wherein in the cancer, the level of nucleic acid encoding CD47 is increased, or CD47 expression is increased, or the level of CD47 protein is increased, or its activity is increased, or its active signaling is enhanced.

24. A non-diagnostic or non-treatment method for detecting CD47 protein in a sample, comprising: (a) Contacting the sample with the isolated antibody or antigen-binding fragment thereof of any one of claims 1-13; and (b) Detect the formation of a complex between the antibody or its antigen-binding fragment and the CD47 protein.

Citation Information

Patent Citations

  • Humanized and chimeric monoclonal antibodies to CD47

    US20150183874A1

  • Anti-CD47 antibodies and methods of use

    US20180201677A1

  • Recombinant altered antibodies and methods of making altered antibodies

    US5225539A

  • Portable GCMS system using getter pump

    US5426300A

  • Humanized immunoglobulins

    US5530101A